



European Association of Urology

**GUIDELINES
ON
NEUROGENIC
LOWER URINARY
TRACT
DYSFUNCTION**

M. Stöhrer, D. Castro-Diaz, E. Chartier-Kastler, G. Kramer,
A. Mattiasson, J.J. Wyndaele

TABLE OF CONTENTS

PAGE

1.	AIM AND STATUS OF THESE GUIDELINES	4
1.1	Purpose	4
1.2	Standardization	4
1.3	References	4
2.	BACKGROUND	4
2.1	Risk factors and epidemiology	4
2.1.1	Peripheral neuropathy	4
2.1.2	Regional spinal anaesthesia	4
2.1.3	Iatrogenic	4
2.1.4	Demyelination (multiple sclerosis)	5
2.1.5	Dementia (Alzheimer, Binswanger, Nasu, Pick)	5
2.1.6	Basal ganglia pathology	5
2.1.7	Cerebrovascular pathology	5
2.1.8	Frontal brain tumours	5
2.1.9	Spinal cord lesions	5
2.1.10	Disc disease	5
2.2	Standardization of terminology	5
2.2.1	Introduction	5
2.2.2	Definitions	5
2.3	Classification	7
2.3.1	Introduction	7
2.3.2	Neuro-urologic classification	8
2.3.3	Neurologic classification	8
2.3.4	Urodynamic classification	8
2.3.5	Functional classification	8
2.3.6	Recommendation for classification	9
2.4	Timing of diagnosis and treatment	9
2.4.1	Guideline for timing of diagnosis and treatment	9
2.5	References	9
3.	DIAGNOSIS	12
3.1	Introduction	12
3.2	History	12
3.2.1	General history	12
3.2.2	Specific history	12
3.2.3	Guidelines for history taking	13
3.3	Physical examination	13
3.3.1	General physical examination	13
3.3.2	Neuro-urologic examination	13
3.3.3	Laboratory tests	14
3.3.4	Guidelines for physical examination	14
3.4	Urodynamics	14
3.4.1	Introduction	14
3.4.2	Urodynamic tests	15
3.4.3	Specific uro-neurophysiologic tests	16
3.4.4	Guidelines for urodynamics and uro-neurophysiology	16
3.5	Typical manifestations of NLUTD	16
3.6	References	16

4.	TREATMENT	18
4.1	Introduction	18
4.2	Non-invasive conservative treatment	18
4.2.1	Assisted bladder emptying	18
4.2.2	Lower urinary tract rehabilitation	19
4.2.3	Drug treatment	19
4.2.4	Electrical neuromodulation	19
4.2.5	External appliances	20
4.2.6	Guidelines for non-invasive conservative treatment	20
4.3	Minimal invasive treatment	20
4.3.1	Catheterization	20
4.3.2	Guidelines for catheterization	20
4.3.3	Intravesical drug treatment	20
4.3.4	Intravesical electrostimulation	21
4.3.5	Bladder neck and urethral procedures	21
4.3.6	Guidelines for minimal invasive treatment	21
4.4	Surgical treatment	22
4.4.1	Urethral and bladder neck procedures	22
4.4.2	Detrusor myectomy (auto-augmentation)	22
4.4.3	Denervation. deafferentation, neurostimulation, neuromodulation	22
4.4.4	Bladder covering by striated muscle	23
4.4.5	Bladder augmentation or substitution	23
4.4.6	Urinary diversion	23
4.5	Guidelines for surgical treatment	24
4.6	References	24
5.	TREATMENT OF VESICO-URETERAL REFLUX	36
5.1	Treatment options	36
5.2	References	36
6.	QUALITY OF LIFE	37
6.1	Considerations	37
6.2	References	37
7.	FOLLOW UP	38
7.1	Considerations	38
7.2	Guidelines for follow-up	38
7.3	References	38
8.	CONCLUSION	39
9.	ABBREVIATIONS	40

1. AIM AND STATUS OF THESE GUIDELINES

1.1 Purpose

The purpose of these clinical guidelines is to provide information on the incidence, definitions, diagnosis, therapy, and follow up observation of the condition of neurogenic lower urinary tract dysfunction (NLUTD), that will be useful for clinical practitioners. These guidelines reflect the current opinion of the experts in this specific pathology and thus represent a state of the art reference for all clinicians as of the date of its presentation to the European Association of Urology.

1.2 Standardization

The terminology used and the diagnostic procedures advised throughout these guidelines follow the recommendations for investigations on the lower urinary tract (LUT) as published by the International Continence Society (ICS) (1-3).

1.3 References

1. Stöhrer M, Goepel M, Kondo A, Kramer G, Madersbacher H, Millard R, Rossier A, Wyndaele JJ. The standardization of terminology in neurogenic lower urinary tract dysfunction with suggestions for diagnostic procedures, *Neurourol Urodyn* 1999; 18:139-158.
2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Subcommittee of the International Continence Society. *Neurourol Urodyn* 2002; 21: 167-178.
3. Schäfer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spångberg A, Sterling AM, Zinner NR, van Kerrebroeck P. Good Urodynamic Practices: Uroflowmetry, Filling Cystometry, and Pressure-Flow Studies. *Neurourol Urodyn* 2002; 21: 261-274.

2. BACKGROUND

2.1 Risk factors and epidemiology

NLUTD may be caused by various diseases and events affecting the nervous systems controlling the LUT. The resulting lower urinary tract dysfunction (LUTD) depends grossly on the location and the extent of the neurologic lesion (cf. 2.3.).

Overall figures on the prevalence of NLUTD in the general population are lacking, but data are available on the prevalence of the underlying conditions and the relative risk of those for the development of NLUTD.

2.1.1 *Peripheral neuropathy*

Diabetes: This common metabolic disorder has a prevalence of about 2.5% in the American population, but the disease may be subclinical for many years. No specific criteria exist for secondary neuropathy in this condition, but it is generally accepted that 50% of the patients will develop somatic neuropathy and 75-100% of those will develop NLUTD (1-2).

Alcohol abuse: This will eventually cause peripheral neuropathy, but its reported prevalence varies widely: 5-15% (3) to 64% (4). The NLUTD is probably more present in patients with liver cirrhosis and the parasympathetic system is attacked more than the sympathetic system (5).

Less prevalent peripheral neuropathies:

- Porphyria — bladder dilatation in up to 12% of patients (6).
- Sarcoidosis — NLUTD rare (7).
- Lumbosacral (8) zone and genital (9) herpes — NLUTD transient in most patients.
- Guillain Barré — Urinary symptoms in 30% of patients, regressive in most (10).

2.1.2 *Regional spinal anaesthesia*

This may cause NLUTD (11) but no prevalence figures were found (12).

2.1.3 *Iatrogenic*

Abdominoperineal resection of rectum or uterus may cause lesions of the lower urinary tract innervation in 10-60% of patients (13,14). The extent of the resection is important: <8% after colostomy only, but 29% after posterior resection (15). Radical prostatectomy is a risk factor also (16).

2.1.4 Demyelination

Multiple sclerosis causes NLUTD in 50-90% of the patients (17-19). NLUTD is the presenting symptom in 2-12% of the patients (20).

2.1.5 Dementia

Alzheimer, Binswanger, Nasu and Pick diseases frequently cause non-specific NLUTD (21-25).

2.1.6 Basal ganglia pathology (Parkinson, Huntington, Shy-Drager, etc.)

Parkinson's disease is accompanied by NLUTD in 37.9-70% (26). In the rare Shy-Drager syndrome almost all patients have NLUTD (27).

2.1.7 Cerebrovascular pathology

This causes hemiplegia with remnant incontinence NLUTD in 20-50% of patients (28 - 30) with decreasing prevalence in the post-insult period (30).

2.1.8 Frontal brain tumours

These tumours can cause LUTD in 24% of the patients (31).

2.1.9 Spinal cord lesions

Spinal cord lesions can be traumatic, vascular, medical, or congenital. An incidence of 30-40 new cases per million population is the accepted average for the USA. Most patients will develop NLUTD (32). For spina bifida and other congenital nerve tube defects, the prevalence in the UK is 8-9 per 10,000 aged 10-69 years with the greatest prevalence in the age group 25-29 years (33), and in the USA 1 per 1000 births (34). About 50% of these children will have detrusor sphincter dyssynergia (DSD) (35).

2.1.10 Disc disease

This is reported to cause NLUTD in 6-18% of the patients (36, 37).

2.2 Standardization of terminology

2.2.1 Introduction

Several groups already presented guidelines for the care of patients with NLUTD for national or international urological community (38-41). These guidelines will evolve further as time goes by. They also contain definitions of various important terms and procedures. The ICS NLUTD standardization report (39) is addressed specifically at the standardization of terminology and urodynamic investigation in this patient group. Other relevant definitions are found in the general ICS standardization report (42).

The definitions from these references, partly adapted, and other definitions that are judged useful for the clinical practice in NLUTD, are listed in section 2.2.2. For specific definitions relating to the urodynamic investigation technique the reader is referred to the appropriate ICS report (39).

2.2.2 Definitions

Acontractility, detrusor — see below under voiding phase

Acontractility, urethral sphincter — see below under storage phase

Autonomic dysreflexia — Increase of sympathetic reflex due to noxious stimuli with symptoms or signs of headache, hypertension, flushing face and perspiration

Capacity — see below under storage phase

Catheterization, indwelling — Emptying of the bladder by a catheter that is introduced (semi-)permanently

Catheterization, intermittent (IC) — Emptying of the bladder by a catheter that is removed after the procedure, mostly at regular intervals

- Aseptic IC — The catheters remain sterile, the genitals are disinfected, and disinfecting lubricant is used

- Clean IC — Disposable or cleansed re-usable catheters, genitals washed

- Sterile IC — Complete sterile setting, including sterile gloves, forceps, gown and mask

- Intermittent self-catheterization (ISC) — IC performed by the patient

Compliance, detrusor — see below under storage phase

Condition — The presence of specific observations associated with characteristic symptoms or signs evidencing relevant pathologic processes

Diary, urinary — Record of times of micturitions and voided volumes, incontinence episodes, pad usage, and other relevant information

- Frequency volume chart (FVC) — Times of micturitions and voided volumes only

- Micturition time chart (MTC) — Times of micturitions only

Filling rate, physiological — Below the predicted maximum: body weight [kg]/4 in ml/s (42, 43)

Hesitancy — Difficulty in initiating micturition; delay in the onset of micturition after the individual is ready to pass urine

Intermittency — Urine flow stops and starts on one or more occasions during voiding

Leak point pressure (LPP) — see below under storage phase

Lower motor neuron lesion (LMNL) — Lesion at or below the S1-S2 spinal cord level

Neurogenic lower urinary tract dysfunction (NLUTD) — Lower urinary tract dysfunction secondary to confirmed pathology of the nervous supply

Observation, specific — Observation made during specific diagnostic procedure

Overactivity, bladder — see below under symptom syndrome

Overactivity, detrusor — see below under storage phase

Rehabilitation, LUT — Non-surgical non-pharmacological treatment for LUT dysfunction

Sign — Observation by the physician including simple means (direct observation, bladder diary, pad weighing) to verify symptoms and classify them

Sphincter, urethral, non-relaxing — see below under voiding phase

Symptom — Subjective indicator of a disease or change in condition as perceived by the patient, carer, or partner that may lead to seek help from health care professionals

Upper motor neuron lesion (UMNL) — Lesion above the S1-S2 spinal cord level

Voiding, balanced — In patients with NLUTD: voiding with physiologic detrusor pressure and low residual (<80 ml or <20% of bladder volume)

Voiding, triggered — Voiding initiated by manoeuvres to elicit reflex detrusor contraction by exteroceptive stimuli

Volume, overactivity — see below under storage phase

Storage phase

- Maximum anaesthetic bladder capacity — Maximum bladder filling volume under deep general or spinal anaesthesia
- Increased daytime frequency — Self-explanatory; the normal frequency can be estimated at about 8 times per day (44)
- Nocturia — Waking at night one or more times to void
- Urgency — The symptom of a sudden compelling desire to pass urine which is difficult to defer
- Urinary incontinence — Any involuntary leakage of urine. This can be specified:
 - Stress urinary incontinence — On effort or exertion, or on sneezing or coughing
 - Urge urinary incontinence — Accompanied by or immediately preceded by urgency
 - Mixed urinary incontinence — Associated with urgency and also exertion, effort, sneezing, or coughing
 - Continuous urinary incontinence
- Bladder sensation categorized as:
 - Normal — Symptom and history: Awareness of bladder filling and increasing sensation up to a strong desire to void.
Urodynamics: First sensation of bladder filling, first desire to void, and strong desire to void at realistic bladder volumes.
 - Increased — Symptom and history: An early and persistent desire to void.
Urodynamics: Any of the three urodynamic parameters mentioned under “normal” persistently at low bladder volume
 - Reduced — Symptom and history: Awareness of bladder filling but no definite desire to void.
Urodynamics: Diminished sensation throughout bladder filling
 - Absent — No sensation of bladder filling or desire to void
 - Non-specific — Perception of bladder filling as abdominal fullness, vegetative symptoms, or spasticity

Definitions valid after urodynamic confirmation only

- Cystometric capacity — Bladder volume at the end of the filling cystometry
- Maximum cystometric capacity — Bladder volume at strong desire to void
- High capacity bladder — Bladder volume at cystometric capacity far over the mean voided volume, estimated from the bladder diary, with no significant increase in detrusor pressure under non-anaesthetized condition
- Normal detrusor function — Little or no pressure increase during filling; no involuntary phasic contractions despite provocation
- Detrusor overactivity — Involuntary detrusor contractions during filling; spontaneous or provoked
Subgroups:
 - Phasic detrusor overactivity — Characteristic phasic contraction
 - Terminal detrusor overactivity — A single contraction at cystometric capacity
- High pressure detrusor overactivity — Maximal detrusor pressure >40 cm H₂O (39,45)

- Overactivity volume — Bladder volume at first occurrence of detrusor overactivity
- Detrusor overactivity incontinence — Self-explanatory
- Leak point pressure
 - Detrusor leak point pressure (DLPP) — Lowest value of detrusor pressure at which leakage is observed in the absence of abdominal strain or detrusor contraction
 - Abdominal leak point pressure — Lowest value of intentionally increased intravesical pressure that provokes leakage in the absence of a detrusor contraction
- Detrusor compliance — Relationship between change in bladder volume (ΔV) and change in detrusor pressure (Δp_{det}): $C = \Delta V / \Delta p_{det}$ [ml/cm H₂O]
- Low detrusor compliance — $C = \Delta V / \Delta p_{det} < 20$ ml/cm H₂O (39)
- Break volume — Bladder volume after which a sudden significant decrease in detrusor compliance is observed
- Urethral sphincter acontractility — No evidence of sphincter contraction during filling, particularly at higher bladder volumes, or during abdominal pressure increase

Voiding phase

- Slow stream — Reduced urine flow rate
- Intermittent stream (intermittency) — Stopping and starting of urine flow during micturition
- Hesitancy — Difficulty in initiating micturition
- Straining — Muscular effort to initiate, maintain, or improve urinary stream
- Terminal dribble — Prolonged final part of micturition when the flow has slowed to a trickle/dribble

Definitions valid after urodynamic confirmation only

- Normal detrusor function — Voluntarily initiated detrusor contraction that causes complete bladder emptying within a normal time span
- Detrusor underactivity — Contraction of reduced strength and/or duration
- Acontractile detrusor — Absent contraction
- Non-relaxing urethral sphincter — Self-explanatory
- Detrusor sphincter dyssynergia (DSD) — Detrusor contraction concurrent with an involuntary contraction of the urethral and/or periurethral striated musculature

Post micturition phase

- Feeling of incomplete emptying (symptom only)
- Post micturition dribble - Involuntary leakage of urine shortly after finishing the micturition

Pain, discomfort or pressure sensation in the lower urinary tract and genitalia that may be related to bladder filling or voiding, may be felt after micturition, or be continuous

Symptom syndrome - Combination of symptoms

- Overactive bladder syndrome — Urgency with or without urge incontinence, usually with frequency and nocturia

Synonyms: Urge syndrome, urgency-frequency syndrome

This syndrome is suggestive for LUTD

2.3 Classification

2.3.1 Introduction

The purpose of classification of NLUTD is to facilitate the understanding and management of NLUTD and to provide a standardized terminology of these disease processes. The normal LUT function depends on neural integration at and between the peripheral, spinal cord, and central nervous systems. The gross type of NLUTD is dependent on the location and the extent of the lesion: suprapontine or pontine, suprasacral spinal cord, or subsacral and peripheral (32,40).

The classification systems for NLUTD are based on either the neurologic substrate (type and location of the neurologic lesion), the neuro-urologic substrate (neurologic lesion and LUTD), the type of LUTD, or are strictly functional. Many descriptive terms were derived from these classification systems, but they are standardized only within any specific system and have little meaning outside the system and can sometimes be confusing.

A perfect classification system is not yet available. Neurologic classification systems, by nature, cannot describe the LUTD completely and vice versa. Individual variations exist in the NLUTD caused by a specific neurologic lesion. Thus for any particular patient the description of the NLUTD should be individualized.

2.3.2 *Neuro-urologic classification*

Bors and Comarr's (46) classic neuro-urologic classification system was deduced from clinical observations of patients with traumatic spinal cord injury. It specifies three elements: location of lesion, completeness of lesion, and co-ordination of LUT.

Hald and Bradley (47) reduced the number of categories in Bors and Comarr's classification. The authors describe their system as a simple neurotopographic classification.

Burgdörfer completed Bors and Comarr's system with information on the LUTD, broken down for detrusor, sphincter, and residual urine. This classification is published elsewhere (48).

2.3.3 *Neurologic classification*

Bradley (49) presented four control loops for the LUT. Loop I are the connections between the central nervous system and the pontine micturition center, loop II the intraspinal pathways between the detrusor to the micturition center (afferent) and the sacral spinal cord (efferent), loop III the sensory axons pathways from the detrusor and the striated urethral sphincter to the sacral spinal cord, and loop IV describes the suprasacral and segmental innervation of the periurethral striated muscles.

2.3.4 *Urodynamic classification*

Lapides (50) classifies the clinical and urodynamic findings into five categories: sensory neurogenic bladder, motor paralytic bladder, autonomous neurogenic bladder, uninhibited neurogenic bladder, and reflex neurogenic bladder.

Krane and Siroky (51) present a descriptive classification of detrusor and sphincter co-ordination observed during urodynamic evaluation in patients with NLUTD, focussed on the functional interaction between detrusor and urethral sphincter.

2.3.5 *Functional classification*

Quesada et al. (52) suggested that a classification based on the functional aspects of the LUT might be more practicable for clinical decision making.

Wein (53) provides a practical approach towards the diagnosis and therapy of LUTD by classifying against the storage and voiding functions of the LUT, and the activity of the detrusor and the urethra.

Fall et al. (54) proposed a more detailed classification of the overactive detrusor. This is included in the ICS classification.

The ICS (42) separates the storage and voiding phases and describes the detrusor and urethral functions in each phase by specific designations (cf. 2.2.).

Madersbacher (40,55) presented a very simple classification that basically is focussed on the therapeutic consequences (fig. 2.1). It is based on the clinical concept that the important differentiation in the diagnosis exists between the situations of high and low detrusor pressure during the filling phase and urethral sphincter relaxation and non-relaxation or DSD during the voiding phase. A non-relaxed sphincter or DSD will cause high detrusor pressure during the voiding phase. This classification is the easiest one for general use in clinical diagnosis of NLUTD.




Figure 2.1. Madersbacher classification system (40) with typical neurogenic lesions

2.3.6 RECOMMENDATION FOR CLASSIFICATION

The Madersbacher classification system (40) (fig. 2.1) is recommended for clinical practice.

2.4 Timing of diagnosis and treatment

Both in congenital and in acquired NLUTD, early diagnosis and treatment is essential as irreversible changes may occur in particular in children with myelomeningocele (56-61), but also in patients with traumatic spinal cord injury (62-64), even if the related neuropathologic signs may be normal (65).

The fact must also be considered that LUTD by itself may be the presenting symptom for neurologic pathology (20,66).

2.4.1 GUIDELINE FOR TIMING OF DIAGNOSIS AND TREATMENT

1. Diagnosis and treatment in NLUTD should be performed as soon as possible.

2.5 REFERENCES

1. Ellenberg M. Development of urinary bladder dysfunction in diabetes mellitus. *Ann Intern Med* 1980; 92: 321-323.
2. Bradley WE. Diagnosis of urinary bladder dysfunction in diabetes mellitus. *Ann Intern Med* 1980; 92: 323-326.
3. Schuckit M. In: Isselbacher KJ, et al. (eds) *Harrison's principles of Internal Medicine*. New York, McGraw-Hill 1981: 1475-1478.
4. Barter F, Tanner AR. Autonomic neuropathy in an alcoholic population. *Postgrad Med J* 1987; 63: 1033-1036.
5. Anonymous. Autonomic neuropathy in liver disease. *Lancet* 1989; 2(8665): 721-722
6. Bloomer JR, Bonkovsky HL. The porphyrias. *Dis Mon* 1989; 35: 1-54.
7. Chapelon C, Ziza JM, Piette JC, Levy Y, Raguin G, Wechsler B, Bitker MO, Blety O, Laplane D, Bousser MG, et al. Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. *Medicine (Baltimore)*; 1990; 69: 261-276.
8. Chen PH, Hsueh HF, Hong CZ. Herpes zoster-associated voiding dysfunction: a retrospective study and literature review. *Arch Phys Med Rehabil* 2002; 83: 1624-1628
9. Greenstein A, Matzkin H, Kaver I, Braf Z. Acute urinary retention in herpes genitalis infection. Urodynamic evaluation. *Urology* 1988; 31: 453-456.
10. Lichtenfeld P. Autonomic dysfunction in the Guillain-Barré syndrome. *Am J Med* 1971; 50: 772-780.
11. Mardirosoff C, Dumont L. Bowel and bladder dysfunction after spinal bupivacaine. *Anesthesiology* 2001; 95: 1306.
12. Auroy Y, Benhamou D, Bargues L, Ecoffey C, Falissard B, Mercier F, Bouaziz H, Samii K. Major

complications of regional anesthesia in France: The SOS Regional Anesthesia Hotline Service. *Anesthesiology* 2002; 97: 1274-1280.

13. Seski JC, Diokno AC. Bladder dysfunction after radical abdominal hysterectomy. *Am J Obstet Gynecol* 1977; 128: 643-651.
14. Sekido N, Kawai K, Akaza H. Lower urinary tract dysfunction as persistent complication of radical hysterectomy. *Int J Urol* 1997; 4: 259-264.
15. Emmett JL. Treatment of vesical dysfunction after operations on rectum and sigmoid. *Surg Clin North Am* 1957; 37: 1009-1017.
16. Zermann DH, Ishigooka M, Wunderlich H, Reichelt O, Schubert J. A study of pelvic floor function pre- and postradical prostatectomy using clinical neurourological investigations, urodynamics and electromyography. *Eur Urol* 2000; 37: 72-78.
17. Holland NJ, Wiesel-Levison P, Schwedelson ES. Survey of neurogenic bladder in multiple sclerosis. *J Neurosurg Nurs* 1981; 13: 337-343.
18. Goldstein I, Siroky MB, Sax DS, Krane RJ. Neurourologic abnormalities in multiple sclerosis. *J Urol* 1982; 128: 541-545.
19. Fowler CJ, van Kerrebroeck PE, Nordenbo A, Van Poppel H. Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. Committee of the European Study Group of SUDIMS (Sexual and Urological Disorders in Multiple Sclerosis) *J Neurol Neurosurg Psychiatry* 1992; 55: 986-989.
20. Bemelmans BL, Hommes OR, Van Kerrebroeck PE, Lemmens WA, Doesburg WH, Debruyne FM. Evidence for early lower urinary tract dysfunction in clinically silent multiple sclerosis. *J Urol* 1991; 145: 1219-1224.
21. Sugiyama T, Hashimoto K, Kiwamoto H, Ohnishi N, Esa A, Park YC, Kurita T. Urinary incontinence in senile dementia of the Alzheimer type (SDAT). *Int J Urol* 1994; 1: 337-340.
22. McGrother C, Resnick M, Yalla SV, Kirschner-Hermanns R, Broseta E, Muller C, Welz-Barth A, Fischer GC, Mattelaer J, McGuire EJ. Epidemiology and etiology of urinary incontinence in the elderly. *World J Urol* 1998; 16 (Suppl 1): S3-S9.
23. Madersbacher H, Awad S, Fall M, Janknegt RA, Stohrer M, Weisner B. Urge incontinence in the elderly-supraspinal reflex incontinence. *World J Urol* 1998; 16 (Suppl 1): S35-S43.
24. Olsen CG, Clasen ME. Senile dementia of the Binswanger's type. *Am Fam Physician* 1998; 58: 2068-2074.
25. Honig LS, Mayeux R. Natural history of Alzheimer's disease. *Aging (Milano)* 2001; 13: 171-82.
26. Murnaghan GF. Neurogenic disorders of the bladder in Parkinsonism. *Br J Urol* 1961; 33:403-409.
27. Salinas JM, Berger Y, De La Rocha RE, Blaivas JG. Urological evaluation in the Shy Drager syndrome. *J Urol* 1986; 135: 741-743.
28. Currie CT. Urinary incontinence after stroke. *Br Med J* 1986; 293: 1322-1323.
29. Codine PH, Pellissier J, Manderscheidt JC, Costa P, Enjalbert M, Perrigot M. Les troubles urinaires au cours des hémiplégies vasculaires. In: Pellissier J (ed) *Hémiplégie vasculaire et médecine de rééducation*. Paris, Masson 1988: 261-269.
30. Barer DH. Continence after stroke: useful predictor or goal of therapy? *Age Ageing* 1989; 18: 183-191.
31. Andrew J, Nathan PW. Lesions of the anterior frontal lobes and disturbances of micturition and defecation. *Brain* 1964; 87: 233 ff.
32. Burns AS, Rivas DA, Ditunno JF. The management of neurogenic bladder and sexual dysfunction after spinal cord injury. *Spine*. 2001; 26 (Suppl): S129-S136.
33. Lawrenson R, Wyndaele JJ, Vlachonikolis I, Farmer C, Glickman S. A UK general practice database study of prevalence and mortality of people with neural tube defects. *Clin Rehabil* 2000; 14: 627-630.
34. Selzman AA, Elder JS, Mapstone TB. Urologic consequences of myelodysplasia and other congenital abnormalities of the spinal cord. *Urol Clin North Am* 1993; 20: 485-504
35. van Gool JD, Dik P, de Jong TP. Bladder-sphincter dysfunction in myelomeningocele. *Eur J Pediatr* 2001; 160: 414-420.
36. Rosomoff HL, Johnston JD, Gallo AE, Ludmer M, Givens FT, Carney FT, Kuehn CA. Cystometry in the evaluation of nerve root compression in the lumbar spine. *Surg Gynecol Obstet* 1963; 117: 263-270.
37. Scott PJ. Bladder paralysis in cauda equina lesions from disc prolapse. *J Bone Joint Surg* 1965; 47: 224-235.
38. Burgdörfer H, Heidler H, Madersbacher H, Melchior H, Palmtag H, Richter R, Richter-Reichhelm M, Rist M, Rübber H, Sauerwein D, Schalkhäuser K, Stöhrer M. Leitlinien zur urologischen Betreuung Querschnittgelähmter. *Urologe A* 1998; 37: 222-228.
39. Stöhrer M, Goepel M, Kondo A, Kramer G, Madersbacher H, Millard R, Rossier A, Wyndaele JJ. The standardization of terminology in neurogenic lower urinary tract dysfunction with suggestions for diagnostic procedures, *Neurourol Urodyn* 1999; 18:139-158.
40. Madersbacher H, Wyndaele JJ, Igawa Y, Chancellor M, Chartier-Kastler E, Kovindha A. Conservative management in neuropathic urinary incontinence. In: *Incontinence, 2nd Edition*, Abrams P, Khoury S,

- Wein A (eds.), Health Publication Ltd, Plymouth, 2002: 697-754.
41. Castro-Diaz D, Barrett D, Grise P, Perkash I, Stöhrer M, Stone A, Vale P. Surgery for the neuropathic patient. In: *Incontinence*, 2nd Edition, Abrams P, Khoury S, Wein A (eds.), Health Publication Ltd, Plymouth, 2002: 865-891.
 42. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Subcommittee of the International Continence Society. *Neurourol Urodyn* 2002; 21: 167-178.
 43. Klevmark B. Natural pressure-volume curves and conventional cystometry. *Scand J Urol Nephrol (Suppl)* 1999; 201: 1-4.
 44. Homma Y, Ando T, Yoshida M, Kageyama S, Takei M, Kimoto K, Ishizuka O, Gotoh M, Hashimoto T. Voiding and incontinence frequencies: variability of diary data and required diary length. *Neurourol Urodyn* 2002; 21: 204-209.
 45. McGuire EJ, Cespedes RD, O'Connell HE. Leak-point pressures. *Urol Clin North Am* 1996; 23: 253-262.
 46. Bors E, Comarr AE. *Neurological urology*. Karger, Basel 1971.
 47. Hald T, Bradley WE. *The neurogenic bladder*. Williams and Wilkins, Baltimore 1982.
 48. Stöhrer M, Kramer G, Löchner-Ernst D, Goepel M, Noll F, Rübber H. Diagnosis and treatment of bladder dysfunction in spinal cord injury patients. *Eur Urol Update Series* 1994; 3: 170-175.
 49. Bradley WE, Timm GW, Scott FB. Innervation of the detrusor muscle and urethra. *Urol Clin North Am* 1974; 1: 3-27.
 50. Lapedes J. Neuromuscular vesical and urethral dysfunction. In: Campbell MF, Harrison JH (eds) *Urology*. WB Saunders, Philadelphia 1970: 1343-1379.
 51. Krane RJ, Siroky MB. Classification of neuro-urologic disorders. In: Krane RJ, Siroky MB (eds) *Clinical neuro-urology*. Little Brown, Boston 1979: 143-158.
 52. Quesada EM, Scott FB, Cardus D. Functional classification of neurogenic bladder dysfunction. *Arch Phys Med Rehabil* 1968; 49: 692-697.
 53. Wein AJ. Pathophysiology and categorization of voiding dysfunction. In: Walsh PC, Retik AB, Vaughan Jr ED, Wein AJ (eds) *Campbell's Urology 7th Edition*. WB Saunders, Philadelphia 1998: 917-926.
 54. Fall M, Ohlsson BL, Carlsson CA. The neurogenic overactive bladder. Classification based on urodynamics. *Br J Urol* 1989; 64: 368-373.
 55. Madersbacher H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. *Paraplegia* 1990; 28: 217-229.
 56. Cass AS, Luxenberg M, Johnson CF, Gleich P. Incidence of urinary tract complications with myelomeningocele. *Urology* 1985; 25: 374-378.
 57. Fernandes ET, Reinberg Y, Vernier R, Gonzalez R. Neurogenic bladder dysfunction in children: Review of pathophysiology and current management. *J Pediat* 1994; 124: 1-7.
 58. Stone AR. Neurourologic evaluation and urologic management of spinal dysraphism. *Neurosurg Clin N Am* 1995; 6: 269-277.
 59. Satar N, Bauer SB, Shefner J, Kelly MD, Darbey MM: The effects of delayed diagnosis and treatment in patients with an occult spinal dysraphism. *J Urol* 1995, 154: 754-758.
 60. Pontari MA, Keating M, Kelly M, Dyro F, Bauer SB: Retained sacral function in children with high level myelodysplasia. *J Urol* 1995; 154: 775-777.
 61. Kaefer M, Pabby A, Kelly M, Darbey M, Bauer SB. Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomeningocele. *J Urol* 1999; 162: 1068-1071.
 62. Wyndaele JJ: Development and evaluation of the management of the neuropathic bladder. *Paraplegia* 1995, 33: 305-307.
 63. Cardenas DD, Mayo ME, Turner LR: Lower urinary changes over time in suprasacral spinal cord injury. *Paraplegia* 1995; 33: 326-329.
 64. Amarenco G: Troubles vesico-sphincteriens d'origine nerveuse. *Rev Prat* 1995, 45: 331-335.
 65. Watanabe T, Vaccaro AR, Kumon H, Welch WC, Rivas DA, Chancellor MB. High incidence of occult neurogenic bladder dysfunction in neurologically intact patients with thoracolumbar spinal injuries. *J Urol* 1998; 159: 965-968.
 66. Ahlberg J, Edlund C, Wikkelsö C, Rosengren L, Fall M. Neurological signs are common in patients with urodynamically verified "idiopathic" bladder overactivity. *Neurourol Urodyn* 2002; 21: 65-70.

3. DIAGNOSIS

3.1 Introduction

Before any functional investigation is planned, an extensive general and specific diagnosis should be performed. Part of this diagnosis is specific for neurogenic pathology and its possible sequelae. The clinical assessment of patients with NLUTD includes and extends that for other LUTD. The latter should consist of a detailed history, bladder diary and a physical examination. In urinary incontinence, leakage should be demonstrated objectively.

These data are indispensable for reliable interpretation of the findings in diagnostic investigations performed subsequently in NLUTD.

3.2 History

3.2.1 General history

The general history should include relevant questions to neurological and congenital abnormalities, information on the previous occurrence and frequency of urinary infections and on relevant surgery. Information must be obtained on medication with known or possible effects on the lower urinary tract (1-3). The general history should also include the assessment of menstrual, sexual and bowel function, and obstetric history (3).

Hereditary or familial risk factors should be recorded. Symptoms of any metabolic disorder or neurological disease that may induce neurogenic lower urinary tract dysfunction must be checked particularly. Specific signs such as pain, infection, hematuria, fever, etc., may justify further particular diagnosis.

A list of items of particular importance is:

- Congenital anomalies with possible neurological impact
- Metabolic disorders with possible neurological impact
- Preceding therapy, including surgical interventions
- Present medication
- Lifestyle factors such as smoking, alcohol, or addictive drug use
- Infections of the urinary tract
- Quality of life

3.2.2 Specific history

Urinary history: This consists of symptoms related to both the storage and the evacuation functions of the lower urinary tract. The onset and the nature of the NLUTD (acute or insidious) should be determined. Specific symptoms and signs must be assessed in NLUTD and if appropriate be compared with the patients' condition before the neurogenic lower urinary tract dysfunction developed. The separate diagnostic fields items should be diagnosed as detailed as possible (3).

- LUTS
- Previous voiding pattern
- Urinary incontinence
- Bladder sensation
- Mode and type of voiding (catheterization!)

The urinary diary gives (semi-)objective information about the number of voidings, daytime and nighttime voiding frequency, volumes voided, and incontinence and urge episodes.

Bowel history: Patients with NLUTD may suffer from a related neurogenic condition of the lower gastrointestinal tract. The bowel history also must address symptoms related to the storage and the evacuation functions and specific symptoms and signs must be compared with the patients' condition before the neurogenic dysfunction developed. Again, the diagnostic items should be detailed (3).

- Ano-rectal symptoms
- Previous defecation pattern
- Faecal incontinence
- Rectal sensation
- Mode and type of defecation

Sexual history: The sexual function may also be impaired because of the neurogenic condition. The details of this history of course differ between men and women (3).

- Genital or sexual dysfunction symptoms
- Previous sexual function
- Sensation in genital area and for sexual functions
- Erection or arousal
- Orgasm
- Ejaculation

Neurologic history: This should concentrate on the following information.

1. Acquired or congenital neurologic condition
2. Neurological symptoms (somatic and sensory), with onset, evolution, and performed therapy
3. Spasticity or autonomic dysreflexia (lesion level above Th6)

3.2.3 GUIDELINES FOR HISTORY TAKING

1. An extensive general history is mandatory, concentrating on past and present symptoms and conditions for urinary, bowel, sexual, and neurologic functions, and on general conditions that might impair any of these.
2. Special attention should be paid to the possible existence of alarm signs, such as pain, infection, hematuria, fever, etc., that warrant further specific diagnosis.
3. Specific history should be taken for each of the four mentioned functions.

3.3 Physical examination

3.3.1 General physical examination

Attention should be paid to the patient's physical and possible mental handicaps with respect to planned diagnostic investigations. Impaired mobility, particularly in the hips, or extreme spasticity may lead to problems in patient positioning in the urodynamics laboratory. Patients with very high neurological lesions may suffer from a significant drop in blood pressure when moved in a sitting or standing position. Subjective indications of bladder filling sensations may be impossible in retarded patients.

Prostate palpation or observation of pelvic organ descensus is made.

3.3.2 Neuro-urologic examination

General neurological examination: This investigates the motor and sensory functions of the body, the limbs and the hand function. A suprapubic globe is searched for and an appreciation of the skin condition in the genital and perineal regions is made.




Figure 3.1. Dermatomes of spinal cord levels L2-S4.




Figure 3.2. Urogenital and other reflexes in lower spinal cord

Specific neuro-urologic examination: This investigation is necessary in patients with NLUTD. It includes several tests for sacral reflex activity and an evaluation of the sensation in the perineal area. Fig. 3.1 shows the different dermatomes and fig. 3.2 the associated reflexes in this area.

Specified information should become available on:

- Sensation S₂-S₅ on both sides of the body
- Reflexes
- Anal sphincter tone
- Volitional contraction of anal sphincter and pelvic floor

A high correlation exists between the clinical neurologic findings and the NLUTD in some types of neuropathy, but less so in other types (4-9). The correspondence is low, for instance, in myelomeningocele patients (6) and in combined traumatic spinal cord lesions, but high in single-level traumatic spinal cord lesions (9).

3.3.3 Laboratory tests

Besides urinalysis and blood chemistry other tests are specifically indicated in patients with NLUTD. The results of these tests should be detailed (3).

- Imaging studies (Sonography, X-ray, MRI)
- Free flowmetry with assessment of residual urine. Because of natural variations, multiple estimations (at least 2-3) are necessary (3,10,11).
- Quantification of urine loss by pad testing if appropriate

3.3.4 GUIDELINES FOR PHYSICAL EXAMINATION

1. Individual patient handicaps should be acknowledged in planning further investigations.
2. The neurological status should be described as completely as possible. Sensations and reflexes in the urogenital area must all be tested.
3. The anal sphincter and pelvic floor functions must be tested extensively.
4. Urinalysis, blood chemistry, imaging, free flowmetry and residual, and incontinence quantification should be performed.

3.4 Urodynamics

3.4.1 Introduction

Urodynamic investigation is the only method to objectify the (dys-)function of the LUT. This investigation is of pivotal interest to describe the status of the LUT in patients with NLUTD.

In these patients, particularly when detrusor overactivity might be present, the invasive urodynamic investigation is even more provocative than in other patients. Any technical source of artefacts must be critically considered. The quality of the urodynamic recording and its interpretation must be ensured (12).

In patients at risk for autonomic dysreflexia, blood pressure assessment during the urodynamic study is advisable.

In many patients with NLUTD, assessment of maximum anaesthetic bladder capacity may be useful.

The rectal ampulla should be empty of stool before the start of the investigation. Medication by drugs that influence the lower urinary tract function should be abandoned at least 48 hours before the investigation (if feasible) or otherwise be taken into account for the interpretation of the data.

All urodynamic findings must be reported in detail and performed according to the ICS technical recommendations and standards (3,12,13).

3.4.2 Urodynamic tests

Bladder diary: This semi-objective qualification of the LUT is a highly advisable diagnostic tool. For reliable interpretation it should be recorded over at least 2-3 days (3,14). Possible pathologic findings: High voiding frequency, very low or very high voided volumes, nocturnal voidings, urgency, incontinence.

Free uroflowmetry and assessment of residual urine: This gives a first impression of the voiding function. It is mandatory before any invasive urodynamics is planned. For reliable information it should be repeated at least 2-3 times (3,10,11). Possible pathologic findings: Low flow rate, low voided volume, intermittent flow, hesitancy, residual urine.

Care must be taken in judging the results in patients who are not able to void in a normal position. Both the flow pattern and the flow rate may be modified by this inappropriate position and by any constructions to divert the flow.

Filling cystometry: The only method to quantify the filling function has limited significance as a solitary procedure. It is much more powerful if combined with bladder pressure measurement during micturition and even more in video urodynamics. This investigation is necessary to document the status of the LUT function during the filling phase. The bladder should be empty at the start of filling. A physiological filling rate should be used with body-warm saline, as fast filling and room-temperature saline are provocative (3). Possible pathologic findings: Detrusor overactivity, low detrusor compliance, abnormal bladder and other sensations, incontinence, incompetent or relaxing urethra.

Detrusor leak point pressure: This specific investigation is important to estimate the risk for the upper urinary tract or for secondary bladder damage. When the DLPP is >40 cm H₂O the upper tract is endangered (3,15). The DLPP is a screening test only, because it gives no impression of the duration of the high pressure during the filling phase, which can be expected to have even more impact on the upper urinary tract (16). A high DLPP thus warrants further testing by video urodynamics to document the reflux also.

Pressure flow study: This measurement reflects the co-ordination between detrusor and urethra or pelvic floor during the voiding phase. It is even more powerful in combination with filling cystometry and with video urodynamics. It is necessary to document the function of the lower urinary tract function during the voiding phase. Possible pathologic findings: Detrusor underactivity/acontractility, DSD, non-relaxing urethra, residual urine.

Most types of obstructions caused by NLUTD are due to DSD (17,18), non-relaxing urethra, or non-relaxing bladder neck (3,19,20). Pressure-flow analysis mostly assesses the amount of mechanical obstruction caused by the urethra's inherent mechanical and anatomical properties and has limited value in patients with neurogenic lower urinary tract dysfunction.

Electromyography: Registration of the activity of the external urethral sphincter, the peri-urethral striated musculature, the anal sphincter, or the striated pelvic floor muscles. The correct interpretation may be difficult due to artefacts introduced by other equipment used. In the urodynamic setting useful as a gross indication of the patient's ability to control the pelvic floor. Possible pathologic findings: Inadequate recruitment on specific stimuli (bladder filling, hyperreflexive contractions, onset of voiding, coughing, Valsalva, etc.).

More detailed analysis (motor unit potentials, single fibre EMG) only possible as part of a neurophysiologic investigation.

Urethral pressure measurement: This investigation has only a very limited place in NLUTD. There exists no basic consensus on parameters indicating pathological findings (21).

Video urodynamics: This combination of filling cystometry and pressure flow study with imaging is the gold standard for urodynamic investigation in NLUTD (3,22,23). Possible pathological findings: All as described under cystometry and pressure flow study, plus morphological pathology of the LUT and the upper urinary tract.

Ambulatory urodynamics: Functional investigation of the urinary tract utilizing predominantly natural filling of the urinary tract and reproducing normal subject activity (24).

This type of study should be considered when office urodynamics do not reproduce the patient's symptoms and complaints. Possible pathologic findings: as under filling cystometry and pressure flow study provided the flow is measured also. It should be kept in mind that during this study the actual bladder volume is unknown.

Provocative tests during urodynamics: The LUT function can be provoked by coughing, triggered voiding, or anal stretch.

Fast filling cystometry with cooled saline (the "ice water test") is considered a discriminative test between UMNL and LMNL (25-30). Patients with UMNL will develop a detrusor contraction if the detrusor muscle is intact, patients with lower lesions will not. It gives false positive results in young children (27) and seems not fully discriminative in other patients (28,29)

A positive bethanechol test (31) (detrusor contraction >25 cm H₂O) was presumed to proof detrusor denervation hypersensitivity and the muscular integrity of an acontractile detrusor, but it turned out to give equivocal results. Recently a variation of this method was reported with intravesical electromotive administration of the bethanechol (32). This test turned out to be both selective and predictive for successful oral bethanechol treatment.

3.4.3 Specific uro-neurophysiologic tests

These tests are advised as part of the neurological work-up of the patient. They comprise:

- Electromyography (in a neurophysiological setting) of pelvic floor muscles, urethral sphincter and/or anal sphincter
- Nerve conduction studies of pudendal nerve
- Reflex latency measurements of bulbocavernosus and anal reflex arcs
- Evoked responses from clitoris or glans penis
- Sensory testing on bladder and urethra

Other elective tests may be asked for specific conditions that became obvious during patient work-up and urodynamic investigations.

Possible pathologic findings are dependent on the type of the test.

3.4.4 GUIDELINES FOR URODYNAMICS AND URO-NEUROPHYSIOLOGY

1. Urodynamic investigation is necessary to document the (dys-)function of the LUT.
2. The recording of a bladder diary is highly advisable.
3. Free uroflowmetry and assessment of residual urine is mandatory before invasive urodynamics is planned.
4. Video urodynamics is the gold standard for invasive urodynamics in patients with NLUTD. Should this not be available, then a filling cystometry continuing into a pressure flow study should be performed.
5. A physiological filling rate and body-warm saline must be used.
6. DLPP is an important investigation in patients with endangered upper tracts.
7. Specific uro-neurophysiological tests are elective procedures.

3.5 Typical manifestations of NLUTD

Typical findings in NLUTD are listed below.

Filling phase

- Hyposensitivity or hypersensitivity
- Vegetative sensations
- Low compliance
- High capacity bladder
- Detrusor overactivity, spontaneous or provoked
- Sphincter acontractility

Voiding phase

- Detrusor acontractility
- DSD
- Non-relaxing urethra
- Non-relaxing bladder neck

These signs warrant further neurological evaluation, as LUTD may be the presenting symptom of NLUTD (33-37).

3.6 REFERENCES

1. Bors E, Turner RD. History and physical examination in neurological urology. J Urol 1960; 83: 759-767.

2. Thuroff JW, Chartier-Kastler E, Corcus J, Humke J, Jonas U, Palmtag H, Tanagho EA. Medical treatment and medical side effects in urinary incontinence in the elderly. *World J Urol* 1998; 16 (Suppl 1): S48-S61.
3. Stöhrer M, Goepel M, Kondo A, Kramer G, Madersbacher H, Millard R, Rossier A, Wyndaele JJ. The standardization of terminology in neurogenic lower urinary tract dysfunction with suggestions for diagnostic procedures, *Neurourol Urodyn* 1999; 18:139-158.
4. Wyndaele JJ, De Sy WA. Correlation between the findings of a clinical neurological examination and the urodynamic dysfunction in children with myelodysplasia. *J Urol* 1985; 133: 638-640.
5. Wyndaele JJ. Correlation between clinical neurological data and urodynamic function in spinal cord injured patients. *Spinal Cord* 1997; 35: 213-216.
6. Keshtgar AS, Rickwood AM. Urological consequences of incomplete cord lesions in patients with myelomeningocele. *Br J Urol* 1998; 82: 258-260.
7. Wyndaele JJ. Is impaired perception of bladder filling during cystometry a sign of neuropathy? *Br J Urol* 1993; 71: 270-273.
8. Kirchof K, Fowler CJ. The value of the Kurtzke Functional Systems Scales in predicting incomplete bladder emptying. *Spinal Cord* 2000; 38: 409-413.
9. Weld KJ, Dmochowski RR. Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. *Urology* 2000; 55: 490-494.
10. Reynard JM, Peters TJ, Lim C, Abrams P. The value of multiple free-flow studies in men with lower urinary tract symptoms. *Br J Urol* 1996; 77: 813-818.
11. Sonke GS, Kiemenev LA, Verbeek AL, Kortmann BB, Debruyne FM, de la Rosette JJ. Low reproducibility of maximum urinary flow rate determined by portable flowmetry. *Neurourol Urodyn* 1999; 18: 183-191.
12. Schäfer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spångberg A, Sterling AM, Zinner NR, van Kerrebroeck P. Good Urodynamic Practices: Uroflowmetry, Filling Cystometry, and Pressure-Flow Studies. *Neurourol Urodyn* 2002; 21: 261-274.
13. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Subcommittee of the International Continence Society. *Neurourol Urodyn* 2002; 21: 167-178.
14. Homma Y, Ando T, Yoshida M, Kageyama S, Takei M, Kimoto K, Ishizuka O, Gotoh M, Hashimoto T. Voiding and incontinence frequencies: variability of diary data and required diary length. *Neurourol Urodyn* 2002; 21: 204-209.
15. McGuire EJ, Cespedes RD, O'Connell HE. Leak-point pressures. *Urol Clin North Am* 1996; 23: 253-262.
16. Linsenmeyer TA, Bagaria SP, Gendron B. The impact of urodynamic parameters on the upper tracts of spinal cord injured men who void reflexly. *J Spinal Cord Med* 1998; 21: 15-20.
17. Krongrad A, Sotolongo JR Jr. Bladder neck dysynergia in spinal cord injury. *Am J Phys Med Rehabil* 1996; 75: 204-207.
18. Weld KJ, Graney MJ, Dmochowski RR. Clinical significance of detrusor sphincter dyssynergia type in patients with post-traumatic spinal cord injury. *Urology* 2000; 56: 565-568.
19. Rossier AB, Fam BA. 5-microtransducer catheter in evaluation of neurogenic bladder function. *Urology* 1986; 27: 371-378.
20. Al-Ali M, Haddad L. A 10 year review of the endoscopic treatment of 125 spinal cord injured patients with vesical outlet obstruction: does bladder neck dyssynergia exist? *Paraplegia* 1996; 34: 34-38.
21. Lose G, Griffiths D, Hosker G, Kulseng-Hanssen S, Perucchini D, Schafer W, Thind P, Versi E. Standardisation of urethral pressure measurement: Report from the Standardisation Sub-Committee of the International Continence Society. *Neurourol Urodyn* 2002; 21: 258-260.
22. Rivas DA, Chancellor MB: Neurogenic vesical dysfunction. *Urol Clin North Am* 1995, 22: 579-591.
23. Madersbacher HG. Neurogenic bladder dysfunction. *Curr Opin Urol* 1999; 9: 303-307.
24. van Waalwijk van Doorn E, Anders K, Khullar V, Kulseng-Hanssen S, Pesce F, Robertson A, Rosario D, Schafer W. Standardisation of ambulatory urodynamic monitoring: Report of the Standardisation Subcommittee of the International Continence Society for Ambulatory Urodynamic Studies. *Neurourol Urodyn* 2000; 19: 113-125.
25. Geirsson G, Fall M, Lindstrom S. The ice-water test - a simple and valuable supplement to routine cystometry. *Br J Urol* 1993; 71: 681-685.
26. Geirsson G, Lindstrom S, Fall M. Pressure, volume and infusion speed criteria for the ice-water test. *Br J Urol* 1994; 73: 498-503.
27. Geirsson G, Lindstrom S, Fall M, Gladh G, Hermansson G, Hjalmas K. Positive bladder cooling test in neurologically normal young children. *J Urol* 1994; 151: 446-448.
28. Petersen T, Chandiramani V, Fowler CJ. The ice-water test in detrusor hyper-reflexia and bladder instability. *Br J Urol* 1997; 79: 163-167.
29. Chancellor MB, Lavelle J, Ozawa H, Jung SY, Watanabe T, Kumon H. Ice-water test in the urodynamic

- evaluation of spinal cord injured patients. *Tech Urol* 1998; 4: 87-91.
30. Ronzoni G, Menchinelli P, Manca A, De Giovanni L. The ice-water test in the diagnosis and treatment of the neurogenic bladder. *Br J Urol* 1997; 79: 698-701.
 31. Lapidus J. Neurogenic bladder. Principles of treatment. *Urol Clin North Am* 1974; 1: 81-97.
 32. Riedl CR, Stephen RL, Daha LK, Knoll M, Plas E, Pfluger H. Electromotive administration of intravesical bethanechol and the clinical impact on acontractile detrusor management: introduction of a new test. *J Urol* 2000; 164: 2108-2111.
 33. Bemelmans BL, Hommes OR, Van Kerrebroeck PE, Lemmens WA, Doesburg WH, Debruyne FM. Evidence for early lower urinary tract dysfunction in clinically silent multiple sclerosis. *J Urol* 1991; 145: 1219-1224.
 34. Lewis MA, Shaw J, Sattar TM, Bannister CM. The spectrum of spinal cord dysraphism and bladder neuropathy in children. *Eur J Pediatr Surg* 1997; 7 (Suppl 1): 35-37.
 35. Wraige E, Borzyskowski M. Investigation of daytime wetting: when is spinal cord imaging indicated? *Arch Dis Child* 2002; 87: 151-155.
 36. Silveri M, Capitanucci ML, Capozza N, Mosiello G, Silvano A, Gennaro MD. Occult spinal dysraphism: neurogenic voiding dysfunction and long-term urologic follow-up. *Pediatr Surg Int* 1997; 12: 148-150.
 37. Ahlberg J, Edlund C, Wikkelsö C, Rosengren L, Fall M. Neurological signs are common in patients with urodynamically verified "idiopathic" bladder overactivity. *Neurourol Urodyn* 2002; 21: 65-70.

4. TREATMENT

4.1 Introduction

The primary aims for treatment of NLUTD and their priorities are (1-5):

1. Protection of the upper urinary tract
2. Improvement of urinary continence
3. Improvement of the patient's quality of life
4. Restoration of (parts of) the normal LUT function

Further considerations are the patient's disability, the cost effectiveness, the technical intricacy, and the possible complications (5).

Preservation of the upper tract function is of paramount importance (1-9). Renal failure was the main factor for mortality in the spinal cord injured patient surviving the trauma (6-9). This has led to the golden rule in treatment of NLUTD: Assure that the detrusor pressure remains within safe limits during both the filling phase and the voiding phase (1-5). This approach has indeed significantly reduced the mortality from urological causes in this patient group (10).

The therapy of urinary incontinence is important for the social rehabilitation of the patient and thus contributes substantially to the quality of life, but is also pivotal in the prevention of urinary tract infection (UTI) (7-9). When no complete continence can be achieved, methods to attain a socially acceptable control of incontinence can be applied.

Complex procedures that might enable a satisfactory restoration or replacement of the LUT function often may limit the patient so much that the quality of life is unacceptably impaired (1).

In patients with high detrusor pressure during the filling phase (detrusor overactivity, low detrusor compliance) or during the voiding phase (DSD, other causes of bladder outlet obstruction) the therapy is aimed primarily at "the conversion of an active, aggressive high-pressure bladder into a passive low-pressure reservoir" despite the resulting residual urine (1).

4.2 Non-invasive conservative treatment

4.2.1 Assisted bladder emptying

Incomplete bladder emptying is a serious risk factor for UTI, for developing high intravesical pressure during the filling phase, and for incontinence. Therefore, methods to improve the voiding process are practised in patients with NLUTD.

Third party bladder expression (Credé): Regrettably, this method is still applied, foremost in infants and young children with myelomeningocele, and sometimes in tetraplegics. The suprapubic downwards compression of the lower abdomen leads to an increase in the intravesical pressure, but also causes a compression of the urethra and thus a functional obstruction (11,12), that may reinforce an already existing high bladder outlet resistance (13) and lead to inefficient emptying (12). Because of the high pressures that may be created during this procedure it is potentially hazardous for the urinary tract (14,15) and thus it is contra-indicated and its use

should be discouraged unless urodynamics shows intravesical pressure to stay within the safe range (1,14-16).

Voiding by abdominal straining (Valsalva): The considerations mentioned under Credé above also hold for the Valsalva manoeuvre (1,12,14,16). As most patients are unable to scale the pressure they exert on the bladder during Valsalva, the risk of exceeding the safe range is present.

For both methods of emptying long-term complications are hardly avoidable (12,14) and the already weak pelvic floor function may be further impaired, thus exacerbating the existing incontinence (16).

Triggered reflex voiding: Stimulation of the sacral or lumbar dermatomes in patients with UMNL can elicit reflex contraction of the detrusor (1,16). Morbidity occurs more often during the first decades of treatment (17-21). This method may be used in patients in whom it is urodynamically safe (1, 16).

4.2.2 Lower urinary tract rehabilitation

Behavioural modification: Prompted voiding, timed voiding (bladder training), and modification of the life pattern in patients with NLUTD are methods to improve the incontinence situation (2,22-25).

Pelvic floor muscle exercises: This training also aims at improving the incontinence. It has proven effective in stress incontinence treatment and for patients with NLUTD it is mainly used in multiple sclerosis (26).

Pelvic floor electrostimulation: To improve the effect of pelvic floor muscle exercises, or to learn the patient how to contract the pelvic floor, or to improve the patient compliance with the exercises, this may be supported by electrostimulation (16,27-29).

Biofeedback: This method can be used for supporting the voiding pattern modification (30-33).

4.2.3 Drug treatment

A medical therapy for NLUTD is not available. Most drugs used only resolve part of the problems, or are adjunct to other measures (34-40).

Detrusor overactivity: This can be treated effectively by anticholinergic substances (23,24,34-54). Their potentiality extends from a small reduction of detrusor overactivity to complete relaxation, depending on therapeutic regimen and individual tolerance. Increased drug tolerance during the basically life-long necessary therapy and the occurrence of adverse effects are topics of concern in patients with NLUTD in particular. Generally, these patients need a higher dose than other patients with overactive detrusor (41-46) and this may lead to an early discontinuation of the therapy because of adverse events (24,41,44-46).

Oxybutynin (36-41,46-49), trospium chloride (39,41,45,50,51), and propiverine (39,43,45,52), are established medical treatments. These drugs have diverse tolerance profiles and thus another anticholinergic may be prescribed if the patient experiences adverse effects on one. Tolteridine has been studied only in children with NLUTD (42). Various other drugs have been tested (16,36,38,47,48,53).

Additional treatment with desmopressin might improve the efficacy of the treatment (54-58).

Detrusor underactivity: No success had been attained with drugs for improving detrusor contractility (16,59-63), but Riedl et al. (64) have successfully applied oral bethanechol treatment in NLUTD patients with detrusor acontractility who responded positive to the electromotive intravesical bethanechol testing.

Decreasing bladder outlet resistance: Alpha-blockers have been used partly successfully for decreasing the bladder outlet resistance (16,65-70).

Increasing bladder outlet resistance: Several drugs show efficacy in the treatment of selected cases of milder stress incontinence, but there are hardly any publications in patients with NLUTD (16,71,72).

4.2.4 Electrical neuromodulation

A strong contraction of the urethral sphincter and/or pelvic floor, but also anal dilatation, manipulation of the genital region, and physical activity reflexly inhibit the micturition (16,73). Whereas the first mechanism is affected by activation of efferent fibres, the latter ones are produced by activation of afferents (16). Electrical stimulation of the pudendal nerve afferents produces a strong inhibition of the micturition reflex and of the detrusor contraction (74). This stimulation then might support the restoration of the balance between excitatory and inhibitory inputs at the spinal or supraspinal level (16,75,76) and it might imply that patients with incomplete lesions will benefit (16,76,77), but patients with complete lesions will not (78).

Stimulation of the tibial nerve afferents has not been applied in patients with NLUTD.

4.2.5 External appliances

When incontinence cannot be resolved by any of the methods described above, the detrusor pressures are in the safe region, eventually after sphincterotomy or bladder neck incision, and furthergoing non-invasive therapy is not feasible, social continence may be achieved by collecting the urine during the incontinence (1,16). Condom catheters with urine collection devices are a practical method for men. Otherwise incontinence pads may offer a reliable solution. In both cases the infection risk must be closely observed (16). Because of the risk of developing high intravesical pressure, the penile clamp is absolutely contra-indicated.

4.2.6 GUIDELINES FOR NON-INVASIVE CONSERVATIVE TREATMENT

1. The first aim of any therapy is the protection of the upper urinary tract.
2. The mainstay of the treatment for overactive detrusor is anticholinergic drug therapy.
3. Rehabilitation and neuromodulation may be effective in selected cases.
4. A condom catheter or pads may reduce the incontinence to a socially acceptable situation.
5. Any method of assisted bladder emptying should be used with the greatest caution.

4.3 Minimal invasive treatment

4.3.1 Catheterization

Intermittent self- or third party catheterization (79,80) is the gold standard for the management of NLUTD (1,16). It is effective in patients with detrusor underactivity or acontractility (1) and in patients with detrusor overactivity if the overactivity can be successfully suppressed for instance by anticholinergic treatment (1,16,34-40).

The catheters used are made from a diversity of materials and the discussions on re-useable or disposable catheters, use of lubricants, aseptic or clean technique are still going on (1,16,81). Sterile IC, as originally proposed by Guttman and Frankel (79) significantly reduces the risk of UTI and/or bacteriuria (1,16,82,83), related to clean IC introduced by Lapidès et al. (80), but the cost issue may be a limiting factor (16,83). Aseptic IC is believed to be in a mid position (1,84,85). Insufficient patient education and the inherent greater risk of UTI in patients with NLUTD are contributing factors (16,85-91). The average frequency of catheterizations per day is 4-6 times. Less frequent catheterization results in higher catheterization volumes and a higher risk of UTI (1,85-90). More frequent catheterization increases the risk of cross infections and other complications (1,85-90).

Other complications may include lower fertility in men and compromising the urethra (16,81), although the direct relation with the IC is discussed controversially. It appears however that the prevalence of these complications increases with the period that the IC has been practised and with the (temporary) use of indwelling catheterization (89).

The prevalence of complications can be limited by adequate patient education, use of non-traumatizing techniques, and adequate precautions to prevent cross-infections (16,91).

Indwelling transurethral catheterization and, although to a lesser extent, suprapubic cystostomy are significant and early risk factors for UTI and other complications (16,21,92-102). Silicone catheters are preferred because they are less susceptible for encrustation and because of the high incidence of latex allergy in the NLUTD population.

4.3.2 GUIDELINES FOR CATHETERIZATION

1. Intermittent catheterization is the standard treatment for patients who are unable to empty the bladder.
2. Patients should be well instructed on the technique and risks of IC.
3. Aseptic IC is the method of choice.
4. The catheter size is 12-14 Fr.
5. The frequency of IC is 4-6 times per day.
6. The bladder volume must remain below 400 ml and the post-IC residual low.
7. Indwelling transurethral and suprapubic catheterization should be used only exceptionally, under close control and the catheter should be changed frequently. Silicone catheters are preferred and should be changed every 2-4 weeks, (coated) latex catheters need to be changed every 1-2 weeks.

4.3.3 Intravesical drug treatment

For the reduction of the detrusor overactivity, anticholinergics can be applied also intravesically (103-112). This might reduce the adverse effects because it metabolizes differently (110) and a greater amount is sequestered in the bladder, even more so with electromotive administration (111,112).

The vanilloids capsaicin and resiniferatoxin desensitize the C-fibers and thereby reduce the detrusor overactivity for a period of a few months until the sensation of these fibers has restored (15,113-121). The dosage is 1-2 mMol capsaicin in 100 ml 30% alcohol or 10-100 nMol resiniferatoxin in 100 ml 10% alcohol for 30 minutes. Resiniferatoxin has an about 1000-fold potency compared to capsaicin, with less pain during the instillation, and was effective in patients refractory to capsaicin (121).

Botulinum toxin causes a long-lasting but reversible chemical denervation that lasts for about 9 months (122-126). The toxin injections are mapped over the detrusor in a dosage that depends on the preparation used. Generalized muscular weakness may be a seldom adverse effect (126).

4.3.4 *Intravesical electrostimulation*

Intravesical electrostimulation (127) enhances the sensation for bladder filling and urge to void and may restore the volitional control of the detrusor (16,128,129). Daily stimulation sessions of 90 minutes with 10 mA pulses of 2 ms duration at a frequency of 20 Hz (129,130) are used for at least one week (130). It appears that patients with peripheral lesions are the best candidates, that the detrusor muscle must be intact, and that at least some afferent connection between the detrusor and the brain must still be present (16,129,130). Also, the positioning of the stimulating electrodes and the bladder filling apparently are important parameters (131). With these precautions, the results in the literature are still not unequivocal: both positive (128,130,132-136) and negative (137,138) results are reported.

4.3.5 *Bladder neck and urethral procedures*

Reduction of the bladder outlet resistance is often necessary to protect the upper urinary tract. This can be achieved not only by surgical interventions (bladder neck or sphincter incision or urethral stent) but also by chemical denervation of the sphincter. Stress incontinence may result and can be managed by external devices (4.2.5).

Botulinum toxin sphincter injection: Detrusor sphincter dyssynergia can be treated effectively by injection with botulinum toxin in a dosage that depends on the preparation used. The dyssynergia is abolished for a few months, necessitating repeat injections. The efficacy of this treatment is high and few adverse effects have been recorded (139-145).

Balloon dilatation: Although favourable immediate results were reported (146), no further reports were found since 1994.

Sphincterotomy: By staged incision, the bladder outlet resistance can be reduced without completely losing the closure function of the urethra (1,14,147). The laser technique appears to be advantageous (1,148,149). Sphincterotomy also needs to be repeated at regular intervals in a substantial proportion of patients (150), but is efficient and without severe adverse effects (1,14,146-151). As secondary narrowing of the bladder neck may occur, combined bladder neck incision might be considered (1,152,153).

Bladder neck incision: This is indicated only for secondary changes at the bladder neck (fibrosis) (1,14,147,153). When the detrusor is hypertrophied and causes thickening of the bladder neck, this procedure makes no sense (1).

Stents: The implantation of urethral stents causes the continence to be dependent on the adequate closure of the bladder neck only (1,5). Although the results are comparable with sphincterotomy and the stenting procedure has a shorter surgery time and reduced hospital stay (154), the costs (1) and possible complications or re-interventions (154-160) are limiting factors in its use.

Increasing the bladder outlet resistance: This can improve the continence condition. Despite early positive results with urethral bulking agents, a relative early loss of continence is reported in patients with NLUTD (5,21,161-166).

Urethral inserts: Urethral plugs or valves for management of (female) stress incontinence have not been applied in patients with NLUTD. The experience with active pumping urethral prosthesis for treatment of the underactive or acontractile detrusor was disappointing (167).

4.3.6 GUIDELINES FOR MINIMAL INVASIVE TREATMENT

1. Guidelines for catheterization are listed separately under 4.3.2.
2. Botulinum toxin injections in the detrusor are the most promising intravesical drug application for reduction of detrusor overactivity.
3. Intravesical electrostimulation may be of value in specific patients.
4. (Laser) sphincterotomy is the standard treatment for DSD or other increased bladder outlet resistance at the sphincteric area. Botulinum sphincter injections will be the first choice in patients ineligible for interventional surgery. Bladder neck incision is effective in a fibrotic bladder neck. Urethral stents still have too many complications.
5. Urethral bulking agents have disappointing long term effect.

4.4 Surgical treatment

4.4.1 Urethral and bladder neck procedures

Increasing the bladder outlet resistance has the inherent risk of causing high intravesical pressure during the filling and even more during the voiding phase. These procedures to treat the sphincteric incontinence are suitable only when the detrusor activity is or can be controlled, when no significant reflux is present. Moreover they require a good condition of the urethra and bladder neck and will mostly lead to perform intermittent catheterization after the procedure (5,168).

Urethral sling: Various materials have been used for this procedure with enduring positive results (5,168-182). The procedure is established in women; for men the artificial sphincter is obviously the first choice (5).

Artificial urinary sphincter: This device stood the test of time in patients with NLUTD (5). It was introduced by Light and Scott (183) for this patient group and the need for revisions (184,185) have decreased significantly with the new generations of devices (175,186-192).

Functional sphincter augmentation: By transposing the gracilis muscle to the bladder neck (193) or to the proximal urethra (194,195) the possibility exists to create a functional autologous sphincter by electrical stimulation (193,195). This would open the possibility to restore the control over the urethral closure.

Bladder neck and urethra reconstruction: The classical Young-Dees-Leadbetter (196) procedure for reconstruction of the bladder neck in children with bladder exstrophy and the Kropp urethral lengthening (197) improved by Salle (198) are established methods to restore continence provided that intermittent catheterization is practised and/or bladder augmentation is performed (175,184,197-211).

4.4.2 Detrusor myectomy (auto-augmentation)

The idea to enlarge a shrunken bladder by removal of lateral detrusor tissue to free the entrapped ureter in a non-functional fibrotic detrusor was put forward by Couvelaire (212). Since its clinical introduction by Cartwright and Snow (213) in children and by Stöhrer (214,215) in adults, this procedure to reduce detrusor overactivity or to improve low detrusor compliance has gained popularity because of its acceptable long-term results, its low surgical burden, its low rate of long term adverse effects, its positive effect on the patient's quality of life, and because it does not preclude further interventions (1,5,45,213-244).

The procedure is performed extraperitoneally under general anesthesia and consists of the dissection of about 20% of the detrusor tissue around the umbilicus, leaving the mucosa intact (1,213-215). A diverticulum will develop, but this may take 1-2 years in adults (1,213-215). The laparoscopic procedure (219,220,222,228,233), the covering of the mucosa at the detrusor defect (transperitoneal!) (217,229,232,234,238), supporting the bladder (213,216,238), or simple incision of the detrusor muscle (detrusor myotomy) (221,240-244) are proposed variations of the procedure but offer no essential advantages.

4.4.3 Denervation, deafferentation, neurostimulation, neuromodulation

Various procedures that were estimated to destroy the peripheral detrusor innervation have been abandoned because of poor long term results and severe complications (5). These procedures include bladder distension, cystolysis, transvaginal denervation (Ingelman-Sundberg procedure) and subtrigonal phenol injections.

Sacral rhizotomy, also known as sacral deafferentation (SDAF), has achieved some success in reducing detrusor overactivity (21,245-254), but it is used nowadays mostly as an adjuvant to sacral anterior root stimulation (255-269). Alternatives for the rhizotomy are sought in this treatment combination (270-273).

Sacral anterior root stimulation (SARS) is aimed at producing a detrusor contraction. The technique was developed by Brindley (274) and is applicable only in complete lesions above the implant location because of its stimulation amplitude over the pain threshold. The urethral sphincter efferents are also stimulated, but as the striated muscle relaxes faster than the smooth muscle of the detrusor, a so-called "post-stimulus voiding" will occur. This approach has been successful in highly selected patients (255-269). By changing the stimulation parameters this method can also induce defecation or erection.

The sacral nerve stimulation or sacral neuromodulation is based on the research by Schmidt and Tanagho (275). This technique stimulates the afferents and thereby probably restores the correct balance between excitatory and inhibitory impulses from and to the pelvic organs at a sacral and supra-sacral level, thus reducing the detrusor overactivity (75,276). It is used either as a temporary procedure using foramen electrodes with an external stimulator, with the expectation of perseverance of the changes after treatment, or as a chronic procedure with an implanted stimulator. In the latter case a test procedure, the percutaneous nerve evaluation (PNE), with an external stimulator is performed before the implant to judge the patient's response. This procedure also has considerable success in selected patients (230,277-283).

On the basis of the successful application of these systems, future developments towards a device that

may be more integrated in the body are under research (284,285).

4.4.4 *Bladder covering by striated muscle*

When the bladder is covered by a (part of) striated muscle that can be stimulated electrically, or ideally could be contracted voluntarily, an acontractile bladder could be restored to perform a voiding function. The rectus abdominis (286) and the latissimus dorsi (287) have been used successfully in patients with NLUTD.

4.4.5 *Bladder augmentation or substitution*

Replacing or expanding the bladder by intestine or other passive expandable coverage will reduce the detrusor compliance and at least reduce the pressure effect of the detrusor overactivity. The inherent complications associated with these procedures include recurrent infection, stone building, perforation or diverticula, possible malignant changes, and for intestine metabolic abnormality, mucus production and impaired bowel function (5,288-290). As the NLUTD patient population's age when the surgery is performed is generally much lower than the patients with bladder malignancy who are elected for this surgery, the possible very long term complications must be appraised in particular. Thus the procedures should be used with caution in NLUTD patients, but may become necessary if all less invasive methods of treatment have failed.

Bladder augmentation, by procedures such as the clam cystoplasty, is a valid option to decrease detrusor pressure and increase bladder capacity whenever more conservative approaches have failed. A number of different techniques have been published. The results of the various procedures are very good and comparable (45,226,230-232,235-237,289-292). Bladder substitution to create a low pressure reservoir may be indicated in patients with severely thick and fibrotic bladder wall. Scaffolds, probably of tissue-engineered material for bladder augmentation or substitution or alternative techniques are promising future options (236,293-300).

4.4.6 *Urinary diversion*

When no other therapy has been successful urinary diversion must be considered for the protection of the upper tract and for the patient's quality of life (5,301).

Continent diversion: This should be the first choice for diversion. In patients for whom indwelling catheterization or suprapubic catheterization is the only feasible treatment option the change to a continent stoma may be a better prospect (5). Some patients with limited dexterity prefer a stoma above using the urethra for catheterization (5). The continent stoma is created following various techniques. All of them however do show frequent complications, including leakage or stenosis (5,302). The short term continence rates are over 80% and good protection of the upper urinary tract is achieved (5,18,301-317). For cosmetic reasons, the umbilicus is often used for the stoma site, but this may have a higher risk of stenosis (305,308,314).

Incontinent diversion: If catheterization is impossible, incontinent diversion with a urine collecting device is indicated. Fortunately, nowadays, this indication is seldom because many appropriate alternatives can be offered (5). Ultimately it could be considered in patients who are wheelchair bound or bed-ridden with intractable and untreatable incontinence, in devastated lower urinary tracts, when the upper urinary tract is severely compromised, and in patients who refuse other therapy (5). An ileal segment is used for the deviation in most cases (5,318-323). The rather poor long term results and the expected complications warrant a permanent follow-up (5).

Undiversion: Long-standing diversions may be successfully undiverted or an incontinent diversion changed to a continent one with the emergence of new and better techniques for control of the detrusor pressure and the incontinence (5). Also, in young patients the body image may play a role (311). The patient must be carefully counselled and must comply meticulously with the instructions (5). Successful undiversion than can be performed (324-326).

4.5 GUIDELINES FOR SURGICAL TREATMENT

1. Detrusor

1.1. Overactive

- 1.1.1. Detrusor myectomy is an acceptable option for the treatment of overactive bladder when more conservative approaches have failed. It is limited invasive and has minimal morbidity.
- 1.1.2. Sacral rhizotomy with SARS in complete lesions and sacral neuromodulation in incomplete lesions are effective treatments in selected patients.
- 1.1.3. Bladder augmentation is an acceptable option to decrease detrusor pressure whenever less invasive procedures have failed. For the treatment of a severely thick or fibrotic bladder wall a bladder substitution might be considered.

1.2. Underactive

- 1.2.1. SARS with rhizotomy and sacral neuromodulation are effective in selected patients.
- 1.2.2. Restoration of a functional bladder by covering with striated muscle is still experimental.

2. Urethra

2.1. Overactive (DSD) - refer to guidelines for minimal invasive treatment (4.3.6)

2.2. Underactive

- 2.2.1. The placement of a urethral sling is an established procedure.
- 2.2.2. The artificial urinary sphincter is very effective.
- 2.2.3. Transposition of the gracilis muscle is still experimental.

4.6 REFERENCES

1. Stöhrer M, Kramer G, Löchner-Ernst D, Goepel M, Noll F, Rübber H. Diagnosis and treatment of bladder dysfunction in spinal cord injury patients. *Eur Urol Update Series* 1994; 3: 170-175.
2. Chua HC, Tow A, Tan ES. The neurogenic bladder in spinal cord injury-pattern and management. *Ann Acad Med Singapore* 1996; 25: 553-557.
3. Burns AS, Rivas DA, Ditunno JF. The management of neurogenic bladder and sexual dysfunction after spinal cord injury. *Spine*. 2001; 26 (Suppl): S129-136.
4. Rickwood AM. Assessment and conservative management of the neuropathic bladder. *Semin Pediatr Surg*. 2002 May;11(2):108-19.
5. Castro-Diaz D, Barrett D, Grise P, Perkash I, Stöhrer M, Stone A, Vale P. Surgery for the neuropathic patient. In: *Incontinence, 2nd Edition*, Abrams P, Khoury S, Wein A (eds.), Health Publication Ltd, Plymouth, 2002: 865-891.
6. Donnelly J, Hackler RH, Bunts RC. Present urologic status of the World War II paraplegic: 25-year follow-up. Comparison with status of the 20-year Korean War paraplegic and 5-year Vietnam paraplegic. *J Urol* 1972; 108: 558-562.
7. Hackler RH. A 25-year prospective mortality study in the spinal cord injured patient: comparison with the long-term living paraplegic. *J Urol* 1977; 117: 486-488.
8. Perkash I, Giroux J. Prevention, treatment, and management of urinary tract infections in neuropathic bladders. *J Am Paraplegia Soc* 1985; 8: 15-17.
9. Sandock DS, Gothe BG, Bodner RD. Trimethoprim-sulfamethoxazole prophylaxis against urinary tract infection in the chronic spinal cord injured patient. *Paraplegia* 1995; 33: 156-160.
10. Frankel HL, Coll JR, Charlifue SW, Whiteneck GG, Gardner BP, Jamous MA, Krishnan KR, Nuseibeh I, Savic G, Sett P. Long-term survival in spinal cord injury: a fifty year investigation. *Spinal Cord* 1998; 36: 266-274.
11. Madersbacher H. The neuropathic urethra: urethrogram and pathophysiologic aspects. *Eur Urol* 1977; 3: 321-332.
12. Barbalius GA, Klauber GT, Blaivas JG. Critical evaluation of the Crede maneuver: a urodynamic study of 207 patients. *J Urol* 1983; 130: 720-723.
13. Clarke SJ, Thomas DG. Characteristics of the urethral pressure profile in flaccid male paraplegics. *Br J Urol* 1981; 53: 157-161.
14. Stöhrer M. Alterations in the urinary tract after spinal cord injury - diagnosis, prevention and therapy of late sequelae. *World J Urol* 1990; 7: 205-211.
15. Reinberg Y, Fleming T, Gonzalez R. Renal rupture after the Crede maneuver. *J Pediatr* 1994; 124: 279-281.
16. Madersbacher H, Wyndaele JJ, Igawa Y, Chancellor M, Chartier-Kastler E, Kovindha A. Conservative management in neuropathic urinary incontinence. In: *Incontinence, 2nd Edition*, Abrams P, Khoury S, Wein A (eds.), Health Publication Ltd, Plymouth, 2002: 697-754.
17. Van Kerrebroeck PE, Koldewijn EL, Scherpenhuizen S, Debruyne FM. The morbidity due to lower urinary tract function in spinal cord injury patients. *Paraplegia* 1993; 31: 320-329.
18. Sekar P, Wallace DD, Waites KB, DeVivo MJ, Lloyd LK, Stover SL, Dubovsky EV. Comparison of long-term renal function after spinal cord injury using different urinary management methods. *Arch Phys Med*

- Rehabil 1997; 78: 992-997.
19. Linsenmeyer TA, Bagaria SP, Gendron B. The impact of urodynamic parameters on the upper tracts of spinal cord injured men who void reflexly. *J Spinal Cord Med* 1998; 21: 15-20.
 20. McKinley WO, Jackson AB, Cardenas DD, DeVivo MJ. Long-term medical complications after traumatic spinal cord injury: a regional model systems analysis. *Arch Phys Med Rehabil* 1999 ; 80: 1402-1410.
 21. Weld KJ, Dmochowski RR. Effect of bladder management on urological complications in spinal cord injured patients. *J Urol* 2000; 163: 768-772.
 22. Menon EB, Tan ES. Bladder training in patients with spinal cord injury. *Urology* 1992; 40: 425-429.
 23. Nijman RJ. Classification and treatment of functional incontinence in children. *BJU Int* 2000; 85 (Suppl 3): 37-42.
 24. Aslan AR, Kogan BA. Conservative management in neurogenic bladder dysfunction. *Curr Opin Urol* 2002; 12: 473-477.
 25. Christ KF, Kornhuber HH. Treatment of neurogenic bladder dysfunction in multiple sclerosis by ultrasound-controlled bladder training. *Arch Psychiatr Nervenkr* 1980; 228: 191-195.
 26. De Ridder D, Vermeulen C, Ketelaer P, Van Poppel H, Baert L. Pelvic floor rehabilitation in multiple sclerosis. *Acta Neurol Belg* 1999; 99: 61-64.
 27. Ishigooka M, Hashimoto T, Hayami S, Suzuki Y, Nakada T, Handa Y. Electrical pelvic floor stimulation: a possible alternative treatment for reflex urinary incontinence in patients with spinal cord injury. *Spinal Cord* 1996; 34: 411-415.
 28. Vahtera T, Haaranen M, Viramo-Koskela AL, Ruutiainen J. Pelvic floor rehabilitation is effective in patients with multiple sclerosis. *Clin Rehabil* 1997; 11: 211-219.
 29. Balcom AH, Wiatrak M, Biefeld T, Rauen K, Langenstroer P. Initial experience with home therapeutic electrical stimulation for continence in the myelomeningocele population. *J Urol* 1997; 158: 1272-1276.
 30. Nørgaard JP, Djurhuus JC. Treatment of detrusor-sphincter dyssynergia by bio-feedback. *Urol Int* 1982; 37: 236-239.
 31. Klarskov P, Heely E, Nyholdt I, Rottensten K, Nordenbo A. Biofeedback treatment of bladder dysfunction in multiple sclerosis. A randomized trial. *Scand J Urol Nephrol (Suppl)* 1994; 157: 61-65.
 32. Chin-Peuckert L, Salle JL. A modified biofeedback program for children with detrusor-sphincter dyssynergia: 5-year experience. *J Urol* 2001; 166: 1470-1475.
 33. Porena M, Costantini E, Rociola W, Mearini E. Biofeedback successfully cures detrusor-sphincter dyssynergia in pediatric patients. *J Urol* 2000; 163: 1927-1931.
 34. Baskin LS, Kogan BA, Benard F. Treatment of infants with neurogenic bladder dysfunction using anticholinergic drugs and intermittent catheterisation. *Br J Urol* 1990; 66: 532-534.
 35. Tanaka H, Kakizaki H, Kobayashi S, Shibata T, Ameda K, Koyanagi T. The relevance of urethral resistance in children with myelodysplasia: its impact on upper urinary tract deterioration and the outcome of conservative management. *J Urol* 1999; 161: 929-932.
 36. Stone AR. Neurourologic evaluation and urologic management of spinal dysraphism. *Neurosurg Clin N Am* 1995; 6: 269-277.
 37. Edelstein RA, Bauer SB, Kelly MD, Darbey MM, Peters CA, Atala A, Mandell J, Colodny AH, Retik AB. The long-term urological response of neonates with myelodysplasia treated proactively with intermittent catheterization and anticholinergic therapy. *J Urol* 1995; 154: 1500-1504.
 38. Hernandez RD, Hurwitz RS, Foote JE, Zimmern PE, Leach GE. Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele. *J Urol* 1994; 152: 1582-1585.
 39. DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. *Drugs* 2003; 63: 153-166.
 40. Buyse G, Verpoorten C, Vereecken R, Casaer P. Treatment of neurogenic bladder dysfunction in infants and children with neurospinal dysraphism with clean intermittent (self)catheterisation and optimized intravesical oxybutynin hydrochloride therapy. *Eur J Pediatr Surg* 1995; 5 Suppl 1: 31-34.
 41. Madersbacher H, Stöhrer M, Richter R, Burgdörfer H, Hachen HJ, Mürtz G. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia. *Br J Urol* 1995; 75: 452-456.
 42. Goessl C, Sauter T, Michael T, Berge B, Staehler M, Miller K. Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. *Urology* 2000; 55: 414-418.
 43. Madersbacher H, Mürtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). *World J Urol* 2001; 19: 324-335.
 44. Schwantes U, Topfmeier P. Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia-chances for improvement of therapy. *Int J Clin Pharmacol Ther* 1999; 37: 209-218.
 45. Madersbacher HG. Neurogenic bladder dysfunction. *Curr Opin Urol* 1999; 9: 303-307
 46. Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor

- hyperreflexia. *J Urol* 1986; 135: 966-968.
47. Zeegers AG, Kiesswetter H, Kramer AE, Jonas U. Conservative therapy of frequency, urgency and urge incontinence: A double-blind clinical trial of flavoxate hydrochloride, oxybutynin chloride, emepronium bromide and placebo. *World J Urol* 1987; 5: 57-61.
 48. Thuroff JW, Bunke B, Ebner A, Faber P, de Geeter P, Hannappel J, Heidler H, Madersbacher H, Melchior H, Schafer W, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. *J Urol* 1991; 145: 813-816.
 49. Kasabian NG, Vlachiotes JD, Lais A, Klumpp B, Kelly MD, Siroky MB, Bauer SB. The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. *J Urol* 1994; 151: 944-945.
 50. Stöhrer M, Bauer P, Giannetti BM, Richter R, Burgdörfer H, Mürtz G. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial. *Urol Int* 1991; 47: 138-143.
 51. Fröhlich G, Bulitta M, Strosser W. Trospium chloride in patients with detrusor overactivity: meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20 mg trospium chloride twice daily. *Int J Clin Pharmacol Ther* 2002; 40: 295-303.
 52. Stöhrer M, Madersbacher H, Richter R, Wehnert J, Dreikorn K. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia—a double-blind, placebo-controlled clinical trial. *Spinal Cord* 1999; 37: 196-200.
 53. Jonas U, Petri E, Kissel J. Effect of flavoxate on hyperactive detrusor muscle. *Eur Urol* 1979; 5: 106-109.
 54. Kinn AC, Larsson PO. Desmopressin: a new principle for symptomatic treatment of urgency and incontinence in patients with multiple sclerosis. *Scand J Urol Nephrol* 1990; 24: 109-112.
 55. Chancellor MB, Rivas DA, Staas WE Jr. DDAVP in the urological management of the difficult neurogenic bladder in spinal cord injury: Preliminary report. *J Am Paraplegia Soc* 1994; 17: 165-167.
 56. Eckford SD, Swami KS, Jackson SR, Abrams PH: Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis. *Br J Urol* 1994; 74: 733-735.
 57. Fredrikson S. Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosis. *Acta Neurol Scand* 1996; 94: 31-34.
 58. Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. *Arch Neurol* 1996; 53: 1270-1275.
 59. Light JK, Scott FB. Bethanechol chloride and the traumatic cord bladder. *J Urol* 1982; 128: 85-87.
 60. Wheeler JS Jr, Robinson CJ, Culkun DJ, Nemchausky BA. Naloxone efficacy in bladder rehabilitation of spinal cord injury patients. *J Urol* 1987; 137: 1202-1205.
 61. Komersova K, Rogerson JW, Conway EL, Lim TC, Brown DJ, Krum H, Jackman GP, Murdoch R, Louis WJ. The effect of levromakalim (BRL 38227) on bladder function in patients with high spinal cord lesions. *Br J Clin Pharmacol* 1995; 39: 207-209.
 62. Wyndaele JJ, van Kerrebroeck P: The effects of 4 weeks treatment with cisapride on cystometric parameters in spinal cord injury patients. A double-blind, placebo controlled study. *Paraplegia* 1995; 33: 625-627.
 63. Costa P, Bressolle F, Sarrazin B, Mosser J, Sabatier R. Dose-related effect of moxisylyte on maximal urethral closing pressure in patients with spinal cord injuries. *Clin Pharmacol Ther* 1993; 53: 443-449.
 64. Riedl CR, Stephen RL, Daha LK, Knoll M, Plas E, Pfluger H. Electromotive administration of intravesical bethanechol and the clinical impact on acontractile detrusor management: introduction of a new test. *J Urol* 2000; 164: 2108-2111.
 65. Swierzewski 3rd SJ, Gormley EA, Belville WD, Sweetser PM, Wan J, McGuire EJ. The effect of terazosin on bladder function in the spinal cord injured patient. *J Urol* 1994; 151: 951-954.
 66. O'Riordan JI, Doherty C, Javed M, Brophy D, Hutchinson M, Quinlan D. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? *J Urol* 1995; 153: 1114-1116.
 67. Perkash I. Efficacy and safety of terazosin to improve voiding in spinal cord injury patients. *J Spinal Cord Med* 1995; 18: 236-239.
 68. Yasuda K, Yamanishi T, Kawabe K, Ohshima H, Morita T. The effect of urapidil on neurogenic bladder: a placebo controlled double-blind study. *J Urol* 1996; 156: 1125-1130.
 69. Sullivan J, Abrams P. Alpha-adrenoceptor antagonists in neurogenic lower urinary tract dysfunction. *Urology* 1999; 53(3 Suppl 3a): 21-27.
 70. Schulte-Baukloh H, Michael T, Miller K, Knispel HH. Alfuzosin in the treatment of high leak-point pressure in children with neurogenic bladder. *BJU Int* 2002 ; 90: 716-720.
 71. Al-Ali M, Salman G, Rasheed A, Al-Ani G, Al-Rubaigy S, Alwan A, Al-Shaikli A. Phenoxybenzamine in the management of neuropathic bladder following spinal cord injury. *Aust N Z J Surg* 1999; 69: 660-663.
 72. Amark P, Beck O. Effect of phenylpropanolamine on incontinence in children with neurogenic bladders.

- A double-blind crossover study. *Acta Paediatr* 1992; 81: 345-350.
73. Fall M, Lindström S. Electrical stimulation. A physiologic approach to the treatment of urinary incontinence. *Urol Clin North Am* 1991; 18: 393-407.
 74. Vodusek DB, Light KJ, Libby JM. Detrusor inhibition induced by stimulation of pudendal nerve afferents. *Neurourol Urodyn* 1986; 5: 381-389.
 75. Bemelmans BL, Mundy AR, Craggs MD. Neuromodulation by implant for treating lower urinary tract symptoms and dysfunction. *Eur Urol* 1999; 36: 81-91.
 76. Primus G, Kramer G. Maximal external electrical stimulation for treatment of neurogenic or non-neurogenic urgency and/or urge incontinence. *Neurourol Urodyn* 1996; 15: 187-194.
 77. Madersbacher H, Kiss G, Mair D. Transcutaneous electrostimulation of the pudendal nerve for treatment of detrusor overactivity. *Neurourol Urodyn* 1995; 14: 501-502.
 78. Prevaire JG, Soler JM, Perrigot M. Is there a place for pudendal nerve maximal electrical stimulation for the treatment of detrusor hyperreflexia in spinal cord injury patients? *Spinal Cord* 1998; 36: 100-103.
 79. Guttmann L, Frankel H. The value of intermittent catheterisation in the early management of traumatic paraplegia and tetraplegia. *Paraplegia* 1966; 4: 63-84.
 80. Lapidus J, Diokno AC, Silber SJ, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. *J Urol* 1972; 107: 458-461.
 81. Wyndaele JJ. Intermittent catheterization: which is the optimal technique? *Spinal Cord* 2002; 40: 432-437.
 82. Schlager TA, Dilks S, Trudell J, Whittam TS, Hendley JO. Bacteriuria in children with neurogenic bladder treated with intermittent catheterization: natural history. *J Pediatr* 1995; 126: 490-496.
 83. Prieto-Fingerhut T, Banovac K, Lynne CM. A study comparing sterile and nonsterile urethral catheterization in patients with spinal cord injury. *Rehabil Nurs* 1997; 22: 299-302.
 84. Matsumoto T, Takahashi K, Manabe N, Iwatsubo E, Kawakami Y. Urinary tract infection in neurogenic bladder. *Int J Antimicrob Agents* 2001; 17: 293-297.
 85. Stöhrer M, Sauerwein D. Der intermittierende Katheterismus bei neurogener Blasenfunktionsstörung. Eine Standortbestimmung aus urologischer Sicht. *Urologe B* 2001; 41: 362-368.
 86. Waller L, Jonsson O, Norlen L, Sullivan L. Clean intermittent catheterization in spinal cord injury patients: long-term followup of a hydrophilic low friction technique. *J Urol* 1995; 153: 345-348.
 87. Perrouin-Verbe B, Labat JJ, Richard I, Mauduyt de la Greve I, Buzelin JM, Mathe JF. Clean intermittent catheterisation from the acute period in spinal cord injury patients. Long term evaluation of urethral and genital tolerance. *Paraplegia* 1995; 33: 619-624.
 88. Bakke A, Digranes A, Hoisæter PA. Physical predictors of infection in patients treated with clean intermittent catheterization: a prospective 7-year study. *Br J Urol* 1997; 79: 85-90.
 89. Günther M, Löchner-Ernst D, Kramer G, Stöhrer M. Auswirkungen des intermittierende aseptischen intermittierenden Katheterismus auf die männliche Harnröhre. *Urologe B* 2001; 41: 359-361.
 90. Wyndaele JJ. Complications of intermittent catheterization: their prevention and treatment. *Spinal Cord* 2002; 40: 536-541.
 91. Sauerwein D. Urinary tract infection in patients with neurogenic bladder dysfunction. *Int J Antimicrob Agents* 2002; 19: 592-597.
 92. Sullivan LP, Davidson PG, Kloss DA, D'Anna JA Jr. Small-bowel obstruction caused by a long-term indwelling urinary catheter. *Surgery* 1990; 107: 228-230.
 93. Chao R, Clowers D, Mayo ME. Fate of upper urinary tracts in patients with indwelling catheters after spinal cord injury. *Urology* 1993; 42: 259-262.
 94. Chancellor MB, Erhard MJ, Kiilholma PJ, Karasick S, Rivas DA. Functional urethral closure with pubovaginal sling for destroyed female urethra after long-term urethral catheterization. *Urology* 1994; 43: 499-505.
 95. Bennett CJ, Young MN, Adkins RH, Diaz F. Comparison of bladder management complication outcomes in female spinal cord injury patients. *J Urol* 1995; 153: 1458-1460.
 96. Larsen LD, Chamberlin DA, Khonsari F, Ahlering TE. Retrospective analysis of urologic complications in male patients with spinal cord injury managed with and without indwelling urinary catheters. *Urology* 1997; 50: 418-422.
 97. West DA, Cummings JM, Longo WE, Virgo KS, Johnson FE, Parra RO. Role of chronic catheterization in the development of bladder cancer in patients with spinal cord injury. *Urology* 1999; 53: 292-297.
 98. Nomura S, Ishido T, Teranishi J, Makiyama K. Long-term analysis of suprapubic cystostomy drainage in patients with neurogenic bladder. *Urol Int* 2000; 65: 185-189.
 99. Mitsui T, Minami K, Furuno T, Morita H, Koyanagi T. Is suprapubic cystostomy an optimal urinary management in high quadriplegics? A comparative study of suprapubic cystostomy and clean intermittent catheterization. *Eur Urol* 2000; 38: 434-438.
 100. Weld KJ, Wall BM, Mangold TA, Steere EL, Dmochowski RR. Influences on renal function in chronic spinal cord injured patients. *J Urol* 2000; 164: 1490-1493.

101. Zermann D, Wunderlich H, Derry F, Schroder S, Schubert J. Audit of early bladder management complications after spinal cord injury in first-treating hospitals. *Eur Urol* 2000; 37: 156-160.
102. Park YI, Linsenmeyer TA. A method to minimize indwelling catheter calcification and bladder stones in individuals with spinal cord injury. *J Spinal Cord Med* 2001; 24: 105-108.
103. Greenfield SP, Fera M. The use of intravesical oxybutynin chloride in children with neurogenic bladder. *J Urol* 1991; 146: 532-534.
104. Glickman S, Tsokkos N, Shah PJ. Intravesical atropine and suppression of detrusor hypercontractility in the neuropathic bladder. A preliminary study. *Paraplegia* 1995; 33: 36-39.
105. Kaplinsky R, Greenfield S, Wan J, Fera M. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder. *J Urol* 1996; 156:753-756.
106. Holland AJ, King PA, Chauvel PJ, O'Neill MK, McKnight DL, Barker AP. Intravesical therapy for the treatment of neurogenic bladder in children. *Aust N Z J Surg* 1997; 67: 731-733.
107. Amark P, Bussman G, Eksborg S. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. *Eur Urol* 1998; 34: 148-153.
108. Haferkamp A, Staehler G, Gerner HJ, Dorsam J. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. *Spinal Cord* 2000; 38: 250-254.
109. Pannek J, Sommerfeld HJ, Botel U, Senge T. Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury. *Urology* 2000; 55: 358-362.
110. Buyse G, Waldeck K, Verpoorten C, Bjork H, Casaer P, Andersson KE. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. *J Urol* 1998; 160: 892-896.
111. Riedl CR, Knoll M, Plas E, Pflüger H. Intravesical electromotive drug administration technique: preliminary results and side effects. *J Urol* 1998; 159: 1851-1856.
112. Di Stasi SM, Giannantoni A, Navarra P, Capelli G, Storti L, Porena M, Stephen RL. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. *J Urol* 2001; 166: 2232-2236.
113. Fowler CJ, Beck RO, Gerrard S, Betts CD, Fowler CG. Related Intravesical capsaicin for treatment of detrusor hyperreflexia. *J Neurol Neurosurg Psychiatry* 1994; 57: 169-173.
114. Geirsson G, Fall M, Sullivan L: Clinical and urodynamic effects of intravesical capsaicin treatment in patients with chronic traumatic spinal detrusor hyperreflexia. *J Urol* 1995; 154: 1825-1829.
115. Cruz F, Guimaraes M, Silva C, Rio ME, Coimbra A, Reis M. Desensitization of bladder sensory fibers by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. *J Urol* 1997; 157: 585-589.
116. Cruz F, Guimaraes M, Silva C, Reis M. Suppression of bladder hyperreflexia by intravesical resiniferatoxin. *Lancet* 1997; 350: 640-641.
117. De Ridder D, Chandiramani V, Dasgupta P, Van Poppel H, Baert L, Fowler CJ. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup. *J Urol* 1997; 158: 2087-2092.
118. Wiart L, Joseph PA, Petit H, Dosque JP, de Seze M, Brochet B, Deminiere C, Ferriere JM, Mazaux JM, N'Guyen P, Barat M. The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double blind placebo controlled study in patients with spinal cord disease. Preliminary results. *Spinal Cord* 1998; 36: 95-99.
119. Lazzeri M, Spinelli M, Beneforti P, Zanollo A, Turini D. Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord diseases. *Scand J Urol Nephrol* 1998; 32: 331-334.
120. de Seze M, Wiart L, Joseph PA, Dosque JP, Mazaux JM, Barat M. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. *Neurourol Urodyn* 1998; 17: 513-523.
121. Chancellor MB, de Groat WC. Related Intravesical capsaicin and resiniferatoxin therapy: Spicing up the ways to treat the overactive bladder. *J Urol* 1999; 162: 3-11.
122. Stöhrer M, Schurch B, Kramer G, Schmid D, Gaul G, Hauri D. Botulinum-A toxin in the treatment of detrusor hyperreflexia in spinal cord injury: A new alternative to medical and surgical procedures? *Neurourol Urodyn* 1999; 18: 401-402.
123. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A (letter). *N Engl J Med* 2000; 342: 665.
124. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. *J Urol* 2000; 164: 692-697.
125. Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH. Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. *Urology* 2002; 59:

- 325-327.
126. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. *Spinal Cord* 2002; 40: 599-600.
 127. Katona F, Benyö L, Lang J. Über intraluminäre Elektrotherapie von verschiedenen paralytischen Zuständen des gastrointestinalen Traktes mit Quadrangulärstrom. *Zentralbl Chir* 1958; 84: 929-933.
 128. Kaplan WE. Intravesical electrical stimulation of the bladder: pro. *Urology* 2000; 56: 2-4.
 129. Ebner A, Jiang C, Lindstrom S. Intravesical electrical stimulation-an experimental analysis of the mechanism of action. *J Urol* 1992; 148: 920-924.
 130. Primus G, Kramer G, Pummer K. Restoration of micturition in patients with acontractile and hypocontractile detrusor by transurethral electrical bladder stimulation. *Neurourol Urodyn* 1996; 15: 489-497.
 131. De Wachter S, Wyndaele JJ. Quest for standardisation of electrical sensory testing in the lower urinary tract: The influence of technique related factors on bladder electrical thresholds. *Neurourol Urodyn* 2003; 22: 118-122.
 132. Katona F, Berenyi M. Intravesical transurethral electrotherapy in meningomyelocele patients. *Acta Paed Acad Sci Hung* 1975; 16: 363-374.
 133. Madersbacher H, Pauer W, Reiner E, Hetzel H, Spanudakis S. Rehabilitation of micturition in patients with incomplete spinal cord lesions by transurethral electrostimulation of the bladder. *Eur Urol* 1982; 28: 111-116.
 134. Madersbacher H. Intravesical electrical stimulation for the rehabilitation of the neuropathic bladder. *Paraplegia* 1990; 28: 349-352.
 135. Lyne CJ, Bellinger MF. Early experience with transurethral electrical bladder stimulation. *J Urol* 1993; 150: 697-699.
 136. Cheng EY, Richards I, Balcom A, Steinhardt G, Diamond M, Rich M, Donovan JM, Carr MC, Reinberg Y, Hurt G, Chandra M, Bauer SB, Kaplan WE. Bladder stimulation therapy improves bladder compliance: results from a multi-institutional trial. *J Urol* 1996; 156: 761-764.
 137. Nicholas JL, Eckstein HB. Endovesical electrotherapy in treatment of urinary incontinence in spina-bifida patients. *Lancet* 1975; 2: 1276-1277.
 138. Pugach JL, Salvin L, Steinhardt GF. Intravesical electrostimulation in pediatric patients with spinal cord defects. *J Urol* 2000; 164: 965-968.
 139. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. *J Urol* 1988; 139: 919-922.
 140. Dykstra DD, Sidi AA. Related Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. *Arch Phys Med Rehabil* 1990; 71: 24-26.
 141. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. *J Urol* 1996; 155: 1023-1029.
 142. Schurch B, Hodler J, Rodic B. Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. *J Neurol Neurosurg Psychiatry* 1997; 63: 474-476.
 143. Gallien P, Robineau S, Verin M, Le Bot MP, Nicolas B, Brissot R. Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. *Arch Phys Med Rehabil* 1998; 79: 715-717.
 144. Petit H, Wiart L, Gaujard E, Le Breton F, Ferriere JM, Laguena A, Joseph PA, Barat M. Related Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. *Spinal Cord* 1998; 36: 91-94.
 145. Wheeler JS Jr, Walter JS, Chintam RS, Rao S. Botulinum toxin injections for voiding dysfunction following SCI. *J Spinal Cord Med* 1998; 21: 227-229.
 146. Chancellor MB, Rivas DA, Abdill CK, Karasick S, Ehrlich SM, Staas WE. Prospective comparison of external sphincter balloon dilatation and prosthesis placement with external sphincterotomy in spinal cord injured men. *Arch Phys Med Rehabil* 1994; 75: 297-305.
 147. Whitmore WF 3rd, Fam BA, Yalla SV. Experience with anteromedian (12 o'clock) external urethral sphincterotomy in 100 male subjects with neuropathic bladders. *Br J Urol* 1978; 50: 99-101.
 148. Burgdörfer H, Bohatyrewicz A. Bladder outlet resistance decreasing operations in spinal cord damaged patients with vesicoureteral reflux. *Paraplegia* 1992; 30: 256-260.
 149. Perkash I. Use of contact laser crystal tip firing Nd:YAG to relieve urinary outflow obstruction in male neurogenic bladder patients. *J Clin Laser Med Surg* 1998; 16: 33-38.
 150. Noll F, Sauerwein D, Stohrer M. Transurethral sphincterotomy in quadriplegic patients: long-term-follow-up. *Neurourol Urodyn* 1995; 14: 351-358.
 151. Reynard JM, Vass J, Sullivan ME, Mamas M. Sphincterotomy and the treatment of detrusor-sphincter dyssynergia: current status, future prospects. *Spinal Cord* 2003; 41: 1-11.

152. Catz A, Luttwak ZP, Agranov E, Ronen J, Shpaser R, Paz A, Lask D, Tamir A, Mukamel E. The role of external sphincterotomy for patients with a spinal cord lesion. *Spinal Cord* 1997; 35: 48-52.
153. Derry F, al-Rubeyi S. Audit of bladder neck resection in spinal cord injured patients. *Spinal Cord* 1998; 36: 345-348.
154. Chancellor MB, Gajewski J, Ackman CF, Appell RA, Bennett J, Binard J, Boone TB, Chetner MP, Crewalk JA, Defalco A, Foote J, Green B, Juma S, Jung SY, Linsenmeyer TA, MacMillan R, Mayo M, Ozawa H, Roehrborn CG, Shenot PJ, Stone A, Vazquez A, Killorin W, Rivas DA. Long-term followup of the North American multicenter UroLume trial for the treatment of external detrusor-sphincter dyssynergia. *J Urol* 1999; 161: 1545-1550.
155. McFarlane IP, Foley SJ, Shah PJ. Related Long-term outcome of permanent urethral stents in the treatment of detrusor-sphincter dyssynergia. *Br J Urol* 1996; 78: 729-732.
156. Low AI, McRae PJ. Use of the Memokath for detrusor-sphincter dyssynergia after spinal cord injury—a cautionary tale. *Spinal Cord* 1998; 36: 39-44.
157. Juan Garcia FJ, Salvador S, Montoto A, Lion S, Balvis B, Rodriguez A, Fernandez M, Sanchez J. Intraurethral stent prosthesis in spinal cord injured patients with sphincter dyssynergia. *Spinal Cord* 1999; 37: 54-57.
158. Chartier-Kastler EJ, Thomas L, Bussel B, Chancellor MB, Richard F, Denys P. A urethral stent for the treatment of detrusor-striated sphincter dyssynergia. *BJU Int* 2000; 86: 52-57.
159. Gajewski JB, Chancellor MB, Ackman CF, Appell RA, Bennett J, Binard J, Boone TB, Chetner MP, Crewalk JA, Defalco A, Foote J, Green B, Juma S, Jung SY, Linsenmeyer TA, Macaluso JN Jr, Macmillan R, Mayo M, Ozawa H, Roehrborn CG, Schmidt J, Shenot PJ, Stone A, Vazquez A, Killorin W, Rivas DA. Removal of UroLume endoprosthesis: experience of the North American Study Group for detrusor-sphincter dyssynergia application. *J Urol* 2000; 163: 773-776.
160. Wilson TS, Lemack GE, Dmochowski RR. UroLume stents: lessons learned. *J Urol* 2002; 167: 2477-2480.
161. Bennett JK, Green BG, Foote JE, Gray M. Collagen injections for intrinsic sphincter deficiency in the neuropathic urethra. *Paraplegia* 1995; 33: 697-700.
162. Silveri M, Capitanucci ML, Mosiello G, Broggi G, De Gennaro M. Endoscopic treatment for urinary incontinence in children with a congenital neuropathic bladder. *Br J Urol* 1998; 82: 694-697.
163. Guys JM, Simeoni-Alias J, Fakhro A, Delarue A. Use of polydimethylsiloxane for endoscopic treatment of neurogenic urinary incontinence in children. *J Urol* 1999; 162: 2133-2135.
164. Kassouf W, Capolicchio G, Berardinucci G, Corcos J. Collagen injection for treatment of urinary incontinence in children. *J Urol* 2001; 165: 1666-1668.
165. Caione P, Capozza N. Endoscopic treatment of urinary incontinence in pediatric patients: 2-year experience with dextranomer/hyaluronic acid copolymer. *J Urol* 2002; 168: 1868-1871.
166. Block CA, Cooper CS, Hawtrey CE. Long-term efficacy of periurethral collagen injection for the treatment of urinary incontinence secondary to myelomeningocele. *J Urol* 2003; 169: 327-329.
167. Schurch B, Suter S, Dubs M. Intraurethral sphincter prosthesis to treat hyporeflexic bladders in women: does it work? *BJU Int* 1999; 84: 789-794.
168. Decter RM. Use of the fascial sling for neurogenic incontinence: lessons learned. *J Urol* 1993; 150: 683-686.
169. Herschorn S, Radomski SB. Fascial slings and bladder neck tapering in the treatment of male neurogenic incontinence. *J Urol* 1992; 147: 1073-1075.
170. Gormley EA, Bloom DA, McGuire EJ, Ritchey ML. Pubovaginal slings for the management of urinary incontinence in female adolescents. *J Urol* 1994; 152: 822-825.
171. Kakizaki H, Shibata T, Shinno Y, Kobayashi S, Matsumura K, Koyanagi T. Fascial sling for the management of urinary incontinence due to sphincter incompetence. *J Urol* 1995; 153: 644-647.
172. Gosalbez R, Castellan M. Defining the role of the bladder-neck sling in the surgical treatment of urinary incontinence in children with neurogenic incontinence. *World J Urol* 1998; 16: 285-291.
173. Barthold JS, Rodriguez E, Freedman AL, Fleming PA, Gonzalez R. Results of the rectus fascial sling and wrap procedures for the treatment of neurogenic sphincteric incontinence. *J Urol* 1999; 161:272-274.
174. Dik P, Van Gool JD, De Jong TP. Urinary continence and erectile function after bladder neck sling suspension in male patients with spinal dysraphism. *BJU Int* 1999; 83: 971-975.
175. Kryger JV, Gonzalez R, Barthold JS. Surgical management of urinary incontinence in children with neurogenic sphincteric incompetence. *J Urol* 2000; 163: 256-263.
176. Walker RD, Erhard M, Starling J. Long-term evaluation of rectus fascial wrap in patients with spina bifida. *J Urol* 2000; 164: 485-486.
177. Kapoor R, Dubey D, Kumar A, Zaman W. Modified bulbar urethral sling procedure for the treatment of male sphincteric incontinence. *J Endourol* 2001; 15: 545-549.
178. Nguyen HT, Bauer SB, Diamond DA, Retik AB. Rectus fascial sling for the treatment of neurogenic sphincteric incontinence in boys: is it safe and effective? *J Urol* 2001; 166: 658-661.
179. Austin PF, Westney OL, Leng WW, McGuire EJ, Ritchey ML. Advantages of rectus fascial slings for

- urinary incontinence in children with neuropathic bladders. *J Urol* 2001; 165: 2369-2371.
180. Mingin GC, Youngren K, Stock JA, Hanna MK. The rectus myofascial wrap in the management of urethral sphincter incompetence. *BJU Int* 2002; 90: 550-553.
 181. Colvert JR 3rd, Kropp BP, Cheng EY, Pope JC 4th, Brock JW 3rd, Adams MC, Austin P, Furness PD 3rd, Koyle MA. The use of small intestinal submucosa as an off-the-shelf urethral sling material for pediatric urinary incontinence. *J Urol* 2002; 168: 1872-1875.
 182. Daneshmand S, Ginsberg DA, Bennet JK, Foote J, Killorin W, Rozas KP, Green BG. Puboprosthetic sling repair for treatment of urethral incompetence in adult neurogenic incontinence. *J Urol* 2003; 169: 199-202.
 183. Light JK, Scott FB. Use of the artificial urinary sphincter in spinal cord injury patients. *J Urol* 1983; 130: 1127-1129.
 184. Sidi AA, Reinberg Y, Gonzalez R. Comparison of artificial sphincter implantation and bladder neck reconstruction in patients with neurogenic urinary incontinence. *J Urol* 1987; 138: 1120-1122.
 185. Belloli G, Campobasso P, Mercurella A. Neuropathic urinary incontinence in pediatric patients: management with artificial sphincter. *J Pediatr Surg* 1992; 27: 1461-1464
 186. Gonzalez R, Merino FG, Vaughn M. Long-term results of the artificial urinary sphincter in male patients with neurogenic bladder. *J Urol* 1995; 154: 769-770.
 187. Levesque PE, Bauer SB, Atala A, Zurakowski D, Colodny A, Peters C, Retik AB. Ten-year experience with the artificial urinary sphincter in children. *J Urol* 1996; 156: 625-628.
 188. Singh G, Thomas DG. Artificial urinary sphincter in patients with neurogenic bladder dysfunction. *Br J Urol* 1996; 77: 252-255.
 189. Fulford SC, Sutton C, Bales G, Hickling M, Stephenson TP. The fate of the 'modern' artificial urinary sphincter with a follow-up of more than 10 years. *Br J Urol* 1997; 79: 713-716.
 190. Elliott DS, Barrett DM. Mayo Clinic long-term analysis of the functional durability of the AMS 800 artificial urinary sphincter: a review of 323 cases. *J Urol* 1998; 159: 1206-1208.
 191. Castera R, Podesta ML, Ruarte A, Herrera M, Medel R. 10-Year experience with artificial urinary sphincter in children and adolescents. *J Urol* 2001; 165: 2373-2376.
 192. Kryger JV, Leveson G, Gonzalez R. Long-term results of artificial urinary sphincters in children are independent of age at implantation. *J Urol* 2001; 165: 2377-2379.
 193. Janknegt RA, Baeten CG, Weil EH, Spaans F. Electrically stimulated gracilis sphincter for treatment of bladder sphincter incontinence. *Lancet* 1992; 340: 1129-1130.
 194. Chancellor MB, Hong RD, Rivas DA, Watanabe T, Crewalk JA, Bourgeois I. Gracilis urethromyoplasty-an autologous urinary sphincter for neurologically impaired patients with stress incontinence. *Spinal Cord* 1997; 35: 546-549.
 195. Chancellor MB, Heesakkers JP, Janknegt RA. Gracilis muscle transposition with electrical stimulation for sphincteric incontinence: a new approach. *World J Urol* 1997; 15: 320-328.
 196. Donnahoo KK, Rink RC, Cain MP, Casale AJ. The Young-Dees-Leadbetter bladder neck repair for neurogenic incontinence. *J Urol* 1999; 161: 1946-1949.
 197. Kropp KA, Angwafo FF. Urethral lengthening and reimplantation for neurogenic incontinence in children. *J Urol* 1986; 135: 533-536.
 198. Salle JL, McLorie GA, Bagli DJ, Khoury AE. Urethral lengthening with anterior bladder wall flap (Pippi Salle procedure): modifications and extended indications of the technique. *J Urol* 1997; 158: 585-590.
 199. Belman AB, Kaplan GW. Experience with the Kropp anti-incontinence procedure. *J Urol* 1989; 141: 1160-1162.
 200. Mollard P, Mouriquand P, Joubert P. Urethral lengthening for neurogenic urinary incontinence (Kropp's procedure): results of 16 cases. *J Urol* 1990; 143: 95-97.
 201. Nill TG, Peller PA, Kropp KA. Management of urinary incontinence by bladder tube urethral lengthening and submucosal reimplantation. *J Urol* 1990; 144: 559-561.
 202. Franco I, Kolligian M, Reda EF, Levitt SB. The importance of catheter size in the achievement of urinary continence in patients undergoing a Young-Dees-Leadbetter procedure. *J Urol* 1994; 152: 710-712.
 203. Rink RC, Adams MC, Keating MA. The flip-flap technique to lengthen the urethra (Salle procedure) for treatment of neurogenic urinary incontinence. *J Urol* 1994; 152: 799-802.
 204. Waters PR, Chehade NC, Kropp KA. Urethral lengthening and reimplantation: incidence and management of catheterization problems. *J Urol* 1997; 158: 1053-1056.
 205. Diamond DA, Bauer SB, Dinlenc C, Hendren WH, Peters CA, Atala A, Kelly M, Retik AB. Normal urodynamics in patients with bladder exstrophy: are they achievable? *J Urol* 1999; 162: 841-844.
 206. Jawaheer G, Rangecroft L. The Pippi Salle procedure for neurogenic urinary incontinence in childhood: a three-year experience. *Eur J Pediatr Surg* 1999; 9 (Suppl 1): 9-11.
 207. Hayes MC, Bulusu A, Terry T, Mouriquand PD, Malone PS. The Pippi Salle urethral lengthening procedure; experience and outcome from three United Kingdom centres. *BJU Int* 1999; 84: 701-705.
 208. Yerkes EB, Adams MC, Rink RC, Pope JC IV, Brock JW 3rd. How well do patients with exstrophy

- actually void? *J Urol* 2000; 164: 1044-1047.
209. Surer I, Baker LA, Jeffs RD, Gearhart JP. Modified Young-Dees-Leadbetter bladder neck reconstruction in patients with successful primary bladder closure elsewhere: a single institution experience. *J Urol* 2001; 165: 2438-2440.
 210. Chan DY, Jeffs RD, Gearhart JP. Determinants of continence in the bladder exstrophy population: predictors of success? *Urology* 2001; 57: 774-777.
 211. Ferrer FA, Tadros YE, Gearhart J. Modified Young-Dees-Leadbetter bladder neck reconstruction: new concepts about old ideas. *Urology* 2001; 58: 791-796.
 212. Couvelaire R. *Chirurgie de la vessie*. Paris, Masson 1955.
 213. Cartwright PC, Snow BW. Bladder autoaugmentation: early clinical experience. *J Urol* 1989; 142: 505-508.
 214. Stöhrer M. Neurogene Blase. In: Jocham D, Miller K (eds) *Praxis der Urologie, Band II*. Stuttgart, Thieme 1992: 257-275.
 215. Stöhrer M, Kramer A, Goepel M, Lochner-Ernst D, Kruse D, Rübber H. Bladder auto-augmentation-an alternative for enterocystoplasty: preliminary results. *Neurourol Urodyn* 1995; 14: 11-23.
 216. Kennelly MJ, Gormley EA, McGuire EJ. Early clinical experience with adult bladder auto-augmentation. *J Urol* 1994; 152: 303-306.
 217. Dewan PA, Stefanek W. Autoaugmentation gastrocystoplasty: early clinical results. *Br J Urol* 1994; 74: 460-464.
 218. Elder JS. Autoaugmentation gastrocystoplasty: early clinical results. *J Urol* 1995; 154: 322-323.
 219. McDougall EM, Clayman RV, Figenshau RS, Pearle MS. Laparoscopic retropubic auto-augmentation of the bladder. *J Urol* 1995; 153: 123-126.
 220. Britanisky RG, Poppas DP, Shichman SN, Mininberg DT, Sosa RE. Laparoscopic laser-assisted bladder autoaugmentation. *Urology* 1995; 46: 31-35.
 221. Rivas DA, Figueroa TE, Chancellor MB. Bladder autoaugmentation. *Tech Urol* 1995; 1: 181-187.
 222. Poppas DP, Uzzo RG, Britanisky RG, Mininberg DT. Laparoscopic laser assisted auto-augmentation of the pediatric neurogenic bladder: early experience with urodynamic followup. *J Urol* 1996; 155: 1057-1060.
 223. Snow BW, Cartwright PC. Bladder autoaugmentation. *Urol Clin North Am* 1996; 23: 323-331.
 224. Stöhrer M, Kramer G, Goepel M, Lochner-Ernst D, Kruse D, Rübber H. Bladder autoaugmentation in adult patients with neurogenic voiding dysfunction. *Spinal Cord* 1997; 35: 456-462.
 225. Swami KS, Feneley RC, Hammonds JC, Abrams P. Detrusor myectomy for detrusor overactivity: a minimum 1-year follow-up. *Br J Urol* 1998; 81: 68-72.
 226. Duel BP, Gonzalez R, Barthold JS. Alternative techniques for augmentation cystoplasty. *J Urol* 1998; 159: 998-1005.
 227. Skobejko-Wlodarska L, Strulak K, Nachulewicz P, Szymkiewicz C. Bladder autoaugmentation in myelodysplastic children. *Br J Urol* 1998; 81 (Suppl 3): 114-116.
 228. Braren V, Bishop MR. Laparoscopic bladder autoaugmentation in children. *Urol Clin North Am* 1998; 25: 533-540.
 229. Dewan PA. Autoaugmentation demucosalized enterocystoplasty. *World J Urol* 1998; 16: 255-261.
 230. Chapple CR, Bryan NP. Surgery for detrusor overactivity. *World J Urol* 1998; 16: 268-273.
 231. Leng WW, Blalock HJ, Fredriksson WH, English SF, McGuire EJ. Enterocystoplasty or detrusor myectomy? Comparison of indications and outcomes for bladder augmentation. *J Urol* 1999; 161: 758-763.
 232. Comer MT, Thomas DF, Trejdosiewicz LK, Southgate J. Reconstruction of the urinary bladder by auto-augmentation, enterocystoplasty, and composite enterocystoplasty. *Adv Exp Med Biol* 1999; 462: 43-47.
 233. Siracusano S, Trombetta C, Liguori G, De Giorgi G, d'Aloia G, Di Benedetto P, Belgrano E. Laparoscopic bladder auto-augmentation in an incomplete traumatic spinal cord injury. *Spinal Cord* 2000; 38: 59-61.
 234. Oge O, Tekgul S, Ergen A, Kendi S. Urothelium-preserving augmentation cystoplasty covered with a peritoneal flap. *BJU Int* 2000; 85: 802-805.
 235. Cranidis A, Nestoridis G. Bladder augmentation. *Int Urogynecol J Pelvic Floor Dysfunct* 2000; 11: 33-40.
 236. Niknejad KG, Atala A. Bladder augmentation techniques in women. *Int Urogynecol J Pelvic Floor Dysfunct* 2000; 11: 156-169.
 237. Westney OL, McGuire EJ. Surgical procedures for the treatment of urge incontinence. *Tech Urol* 2001; 7: 126-132.
 238. Perovic SV, Djordjevic ML, Kekic ZK, Vukadinovic VM. Bladder autoaugmentation with rectus muscle backing. *J Urol* 2002; 168: 1877-1880.
 239. Marte A, Di Meglio D, Cotrufo AM, Di Iorio G, De Pasquale M, Vessella A. A long-term follow-up of autoaugmentation in myelodysplastic children. *BJU Int* 2002; 89: 928-931.
 240. Ehrlich RM, Gershman A. Laparoscopic seromyotomy (auto-augmentation) for non-neurogenic neurogenic bladder in a child: initial case report. *Urology* 1993; 42: 175-178.
 241. Stothers L, Johnson H, Arnold W, Coleman G, Tearle H. Bladder autoaugmentation by vesicomomyotomy

- in the pediatric neurogenic bladder. *Urology* 1994; 44:110-113.
242. Ter Meulen PH, Heesakkers JP, Janknegt RA. A study on the feasibility of vesicomyotomy in patients with motor urge incontinence. *Eur Urol* 1997; 32: 166-169.
 243. Surer I, Elicevik M, Ozturk H, Sakarya MT, Cetinkursun S. An alternative approach to bladder autoaugmentation. *Tech Urol* 1999; 5: 100-103.
 244. Potter JM, Duffy PG, Gordon EM, Malone PR. Detrusor myotomy: a 5-year review in unstable and non-compliant bladders. *BJU Int* 2002; 89: 932-935.
 245. Nagib A, Leal J, Voris HC. Successful control of selective anterior sacral rhizotomy for treatment of spastic bladder and ureteric reflux in paraplegics. *Med Serv J Can* 1966; 22: 576-581.
 246. Manfredi RA, Leal JF. Selective sacral rhizotomy for the spastic bladder syndrome in patients with spinal cord injuries. *J Urol* 1968; 100: 17-20.
 247. Toczek SK, McCullough DC, Gargour GW, Kachman R, Baker R, Luessenhop AJ. Selective sacral rootlet rhizotomy for hypertonic neurogenic bladder. *J Neurosurg* 1975; 42: 567-574.
 248. Diokno AC, Vinson RK, McGillicuddy J. Treatment of the severe uninhibited neurogenic bladder by selective sacral rhizotomy. *J Urol* 1977; 118: 299-301.
 249. Rockswold GL, Chou SN, Bradley WE. Re-evaluation of differential sacral rhizotomy for neurological bladder disease. *J Neurosurg* 1978; 48: 773-778.
 250. Young B, Mulcahy JJ. Percutaneous sacral rhizotomy for neurogenic detrusor hyperreflexia. *J Neurosurg* 1980; 53: 85-87.
 251. Franco I, Storrs B, Firlit CF, Zebold K, Richards I, Kaplan WE. Selective sacral rhizotomy in children with high pressure neurogenic bladders: preliminary results. *J Urol* 1992; 148: 648-650.
 252. Gasparini ME, Schmidt RA, Tanagho EA. Selective sacral rhizotomy in the management of the reflex neuropathic bladder: a report on 17 patients with long-term followup. *J Urol* 1992; 148: 1207-1210.
 253. Schneidau T, Franco I, Zebold K, Kaplan W. Selective sacral rhizotomy for the management of neurogenic bladders in spina bifida patients: long-term followup. *J Urol* 1995; 154: 766-768.
 254. Hohenfellner M, Pannek J, Botel U, Dahms S, Pfitzenmaier J, Fichtner J, Hutschenreiter G, Thuroff JW. Sacral bladder denervation for treatment of detrusor hyperreflexia and autonomic dysreflexia. *Urology* 2001; 58: 28-32.
 255. Arnold EP, Gowland SP, MacFarlane MR, Bean AR, Uitley WL. Sacral anterior root stimulation of the bladder in paraplegics. *Aust N Z J Surg* 1986; 56: 319-324.
 256. MacDonagh RP, Forster DM, Thomas DG. Urinary continence in spinal injury patients following complete sacral posterior rhizotomy. *Br J Urol* 1990; 66: 618-622.
 257. Sauerwein D, Ingunza W, Fischer J, Madersbacher H, Polkey CE, Brindley GS, Colombel P, Teddy P. Extradural implantation of sacral anterior root stimulators. *J Neurol Neurosurg Psychiatry* 1990; 53: 681-684.
 258. Madersbacher H, Fischer J. Sacral anterior root stimulation: prerequisites and indications. *Neurourol Urodyn* 1993; 12: 489-494.
 259. Koldewijn EL, Van Kerrebroeck PE, Rosier PF, Wijkstra H, Debruyne FM. Bladder compliance after posterior sacral root rhizotomies and anterior sacral root stimulation. *J Urol* 1994; 151: 955-960.
 260. Singh G, Thomas DG. Intravesical oxybutinin in patients with posterior rhizotomies and sacral anterior root stimulators. *Neurourol Urodyn* 1995; 14: 65-71.
 261. Van Kerrebroeck PE, Koldewijn EL, Rosier PF, Wijkstra H, Debruyne FM. Results of the treatment of neurogenic bladder dysfunction in spinal cord injury by sacral posterior root rhizotomy and anterior sacral root stimulation. *J Urol* 1996; 155: 1378-1381.
 262. Schurch B, Rodic B, Jeanmonod D. Posterior sacral rhizotomy and intradural anterior sacral root stimulation for treatment of the spastic bladder in spinal cord injured patients. *J Urol* 1997; 157: 610-614.
 263. Van Kerrebroeck EV, van der Aa HE, Bosch JL, Koldewijn EL, Vorsteveld JH, Debruyne FM. Sacral rhizotomies and electrical bladder stimulation in spinal cord injury. Part I: Clinical and urodynamic analysis. Dutch Study Group on Sacral Anterior Root Stimulation. *Eur Urol* 1997; 31: 263-271.
 264. Egon G, Barat M, Colombel P, Visentin C, Isambert JL, Guerin J. Implantation of anterior sacral root stimulators combined with posterior sacral rhizotomy in spinal injury patients. *World J Urol* 1998; 16: 342-349.
 265. Schumacher S, Bross S, Scheepe JR, Alken P, Junemann KP. Restoration of bladder function in spastic neuropathic bladder using sacral deafferentation and different techniques of neurostimulation. *Adv Exp Med Biol* 1999; 462: 303-309.
 266. Van der Aa HE, Alleman E, Nene A, Snoek G. Sacral anterior root stimulation for bladder control: clinical results. *Arch Physiol Biochem* 1999; 107: 248-256.
 267. Everaert K, Derie A, Van Laere M, Vandekerckhove T. Bilateral S3 nerve stimulation, a minimally invasive alternative treatment for postoperative stress incontinence after implantation of an anterior root stimulator with posterior rhizotomy: a preliminary observation. *Spinal Cord* 2000; 38: 262-264.

268. Creasey GH, Grill JH, Korsten M, U HS, Betz R, Anderson R, Walter J. An implantable neuroprosthesis for restoring bladder and bowel control to patients with spinal cord injuries: a multicenter trial. *Arch Phys Med Rehabil* 2001; 82: 1512-1519.
269. Vignes JR, Liguoro D, Sesay M, Barat M, Guerin J. Dorsal rhizotomy with anterior sacral root stimulation for neurogenic bladder. *Stereotact Funct Neurosurg* 2001; 76: 243-245.
270. Rijkhoff NJ, Hendriks LB, van Kerrebroeck PE, Debruyne FM, Wijkstra H. Selective detrusor activation by electrical stimulation of the human sacral nerve roots. *Artif Organs* 1997; 21: 223-226.
271. Schumacher S, Bross S, Scheepe JR, Seif C, Junemann KP, Alken P. Extradural cold block for selective neurostimulation of the bladder: development of a new technique. *J Urol* 1999; 161: 950-954.
272. Kirkham AP, Knight SL, Craggs MD, Casey AT, Shah PJ. Neuromodulation through sacral nerve roots 2 to 4 with a Finetech-Brindley sacral posterior and anterior root stimulator. *Spinal Cord* 2002; 40: 272-281.
273. Bhadra N, Grunewald V, Creasey G, Mortimer JT. Selective suppression of sphincter activation during sacral anterior nerve root stimulation. *NeuroUrol Urodyn* 2002; 21: 55-64.
274. Brindley GS. An implant to empty the bladder or close the urethra. *J Neurol Neurosurg Psychiatry* 1977; 40: 358-369.
275. Schmidt RA, Tanagho EA. Feasibility of controlled micturition through electric stimulation. *Urol Int* 1979; 34: 199-230.
276. Braun PM, Baezner H, Seif C, Boehler G, Bross S, Eschenfelder CC, Alken P, Hennerici M, Juenemann P. Alterations of cortical electrical activity in patients with sacral neuromodulator. *Eur Urol* 2002; 41: 562-566.
277. Tanagho EA, Schmidt RA, Orvis BR. Neural stimulation for control of voiding dysfunction: a preliminary report in 22 patients with serious neuropathic voiding disorders. *J Urol* 1989; 142: 340-345.
278. Bosch JL, Groen J. Treatment of refractory urge urinary incontinence with sacral spinal nerve stimulation in multiple sclerosis patients. *Lancet* 1996; 348: 717-719.
279. Bosch JL, Groen J. Neuromodulation: urodynamic effects of sacral (S3) spinal nerve stimulation in patients with detrusor instability or detrusor hyperreflexia. *Behav Brain Res* 1998; 92: 141-150.
280. Hohenfellner M, Schultz-Lampel D, Dahms S, Matzel K, Thuroff JW. Bilateral chronic sacral neuromodulation for treatment of lower urinary tract dysfunction. *J Urol* 1998; 160: 821-824.
281. Chartier-Kastler EJ, Ruud Bosch JL, Perrigot M, Chancellor MB, Richard F, Denys P. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. *J Urol* 2000; 164: 1476-1480.
282. Groen J, van Mastrigt R, Bosch JL. Computerized assessment of detrusor instability in patients treated with sacral neuromodulation. *J Urol* 2001; 165: 169-173.
283. Hohenfellner M, Humke J, Hampel C, Dahms S, Matzel K, Roth S, Thuroff JW, Schultz-Lampel D. Chronic sacral neuromodulation for treatment of neurogenic bladder dysfunction: long-term results with unilateral implants. *Urology* 2001; 58: 887-892.
284. Haugland M, Sinkjaer T. Interfacing the body's own sensing receptors into neural prosthesis devices. *Technol Health Care* 1999; 7: 393-399.
285. Jezernik S, Craggs M, Grill WM, Creasey G, Rijkhoff NJ. Electrical stimulation for the treatment of bladder dysfunction: current status and future possibilities. *Neurol Res* 2002; 24: 413-430.
286. Zhang YH, Shao QA, Wang JM. Enveloping the bladder with displacement of flap of the rectus abdominis muscle for the treatment of neurogenic bladder. *J Urol* 1990; 144: 1194-1195.
287. Stenzl A, Ninkovic M, Kolle D, Knapp R, Anderl H, Bartsch G. Restoration of voluntary emptying of the bladder by transplantation of innervated free skeletal muscle. *Lancet* 1998; 351: 1483-1485.
288. Vajda P, Kaiser L, Magyarlaki T, Farkas A, Vastyan AM, Pinter AB. Histological findings after colocystoplasty and gastrocystoplasty. *J Urol* 2002; 168: 698-701.
289. Greenwell TJ, Venn SN, Mundy AR. Augmentation cystoplasty. *BJU Int* 2001; 88: 511-525.
290. Gough DC. Enterocystoplasty. *BJU Int* 2001; 88: 739-743.
291. Quek ML, Ginsberg DA. Long-term urodynamics followup of bladder augmentation for neurogenic bladder. *J Urol* 2003; 169: 195-198.
292. Chartier-Kastler EJ, Mongiat-Artus P, Bitker MO, Chancellor MB, Richard F, Denys P. Long-term results of augmentation cystoplasty in spinal cord injury patients. *Spinal Cord* 2000; 38: 490-494.
293. Piechota HJ, Dahms SE, Probst M, Gleason CA, Nunes LS, Dahiya R, Lue TF, Tanagho EA. Functional rat bladder regeneration through xenotransplantation of the bladder acellular matrix graft. *Br J Urol* 1998; 81: 548-559.
294. Sievert KD, Tanagho EA. Organ-specific acellular matrix for reconstruction of the urinary tract. *World J Urol* 2000; 18: 19-25.
295. Kropp BP, Cheng EY. Bioengineering organs using small intestinal submucosa scaffolds: in vivo tissue-engineering technology. *J Endourol* 2000; 14: 59-62.
296. Liatsikos EN, Dinlenc CZ, Kapoor R, Bernardo NO, Smith AD. Tissue expansion: a promising trend for

- reconstruction in urology. *J Endourol* 2000;14: 93-96.
297. Atala A. New methods of bladder augmentation. *BJU Int* 2000; 85 (Suppl 3): 24-34
 298. Reddy PP, Barrieras DJ, Wilson G, Bagli DJ, McLorie GA, Khoury AE, Merguerian PA. Regeneration of functional bladder substitutes using large segment acellular matrix allografts in a porcine model. *J Urol* 2000; 164: 936-941.
 299. Kawai K, Hattori K, Akaza H. Tissue-engineered artificial urothelium. *World J Surg* 2000; 24: 1160-1162.
 300. Schalow EL, Kirsch AJ. Advances in bladder augmentation. *Curr Urol Rep* 2002; 3: 125-130.
 301. O'Donnell WF. Urological management in the patient with acute spinal cord injury. *Crit Care Clin* 1987; 3: 599-617.
 302. Bennett JK, Gray M, Green BG, Foote JE. Continent diversion and bladder augmentation in spinal cord-injured patients. *Semin Urol* 1992; 10: 121-132.
 303. Robertson CN, King LR. Bladder substitution in children. *Urol Clin North Am* 1986; 13: 333-344.
 304. Duckett JW, Lotfi AH. Appendicovesicostomy (and variations) in bladder reconstruction. *J Urol* 1993; 149: 567-569.
 305. Moreno JG, Chancellor MB, Karasick S, King S, Abdill CK, Rivas DA. Improved quality of life and sexuality with continent urinary diversion in quadriplegic women with umbilical stoma. *Arch Phys Med Rehabil* 1995; 76: 758-762.
 306. Suzer O, Vates TS, Freedman AL, Smith CA, Gonzalez R. Results of the Mitrofanoff procedure in urinary tract reconstruction in children. *Br J Urol* 1997; 79: 279-282.
 307. Mollard P, Gauriau L, Bonnet JP, Mure PY. Continent cystostomy (Mitrofanoff's procedure) for neurogenic bladder in children and adolescent (56 cases: long-term results). *Eur J Pediatr Surg* 1997; 7: 34-37.
 308. Sylora JA, Gonzalez R, Vaughn M, Reinberg Y. Intermittent self-catheterization by quadriplegic patients via a catheterizable Mitrofanoff channel. *J Urol* 1997;157: 48-50.
 309. Ulman I, Ergun O, Avanoğlu A, Gokdemir A. The place of Mitrofanoff neourethra in the repair of exstrophy-epispadias complex. *Eur J Pediatr Surg* 1998; 8: 352-354.
 310. Cain MP, Casale AJ, King SJ, Rink RC. Appendicovesicostomy and newer alternatives for the Mitrofanoff procedure: results in the last 100 patients at Riley Children's Hospital. *J Urol* 1999; 162: 1749-1752.
 311. Stein R, Fisch M, Ermert A, Schwarz M, Black P, Filipas D, Hohenfellner R. Urinary diversion and orthotopic bladder substitution in children and young adults with neurogenic bladder: a safe option for treatment? *J Urol* 2000; 163: 568-573.
 312. Liard A, Segulier-Lipszyc E, Mathiot A, Mitrofanoff P. The Mitrofanoff procedure: 20 years later. *J Urol* 2001; 165: 2394-2398.
 313. Kajbafzadeh AM, Chubak N. Simultaneous Malone antegrade continent enema and Mitrofanoff principle using the divided appendix: report of a new technique for prevention of stoma complications. *J Urol* 2001; 165: 2404-2409.
 314. Van Savage JG, Yepuri JN. Transverse retubularized sigmoidovesicostomy continent urinary diversion to the umbilicus. *J Urol* 2001; 166: 644-647.
 315. Lowe JB, Furness PD 3rd, Barqawi AZ, Koyle MA. Surgical management of the neuropathic bladder. *Semin Pediatr Surg* 2002; 11: 120-127.
 316. Clark T, Pope JC 4th, Adams C, Wells N, Brock JW 3rd. Factors that influence outcomes of the Mitrofanoff and Malone antegrade continence enema reconstructive procedures in children. *J Urol* 2002; 168: 1537-1540.
 317. Richter F, Stock JA, Hanna MK. Continent vesicostomy in the absence of the appendix: three methods in 16 children. *Urology* 2002; 60: 329-334.
 318. Shapiro SR, Lebowitz R, Colodny AH. Fate of 90 children with ileal conduit urinary diversion a decade later: analysis of complications, pyelography, renal function and bacteriology. *J Urol* 1975; 114: 289-295.
 319. Hald T, Hebjorn S. Vesicostomy—an alternative urine diversion operation. Long term results. *Scand J Urol Nephrol* 1978; 12: 227-231.
 320. Cass AS, Luxenberg M, Gleich P, Johnson CF. A 22-year followup of ileal conduits in children with a neurogenic bladder. *J Urol* 1984; 132: 529-531.
 321. Schwartz SL, Kennelly MJ, McGuire EJ, Faerber GJ. Incontinent ileo-vesicostomy urinary diversion in the treatment of lower urinary tract dysfunction. *J Urol* 1994; 152: 99-102.
 322. Atan A, Konety BR, Nangia A, Chancellor MB. Advantages and risks of ileovesicostomy for the management of neuropathic bladder. *Urology* 1999; 54: 636-640.
 323. Gudziak MR, Tiguert R, Puri K, Gheiler EL, Triest JA. Management of neurogenic bladder dysfunction with incontinent ileovesicostomy. *Urology* 1999; 54:1008-1011.
 324. Borden TA, McGuire EJ, Woodside JR, Allen TD, Bauer SB, Firlit CF, Gonzales ET, Kaplan WE, King LR, Klauber GT, Perlmutter AD, Thornbury JR, Weiss RM. Urinary undiversion in patients with myelodysplasia and neurogenic bladder dysfunction. Report of a workshop. *Urology* 1981; 18: 223-228.
 325. Gonzalez R, Sidi AA, Zhang G. Urinary undiversion: indications, technique and results in 50 cases.

J Urol 1986; 136: 13-16.

326. Herschorn S, Rangaswamy S, Radomski SB. Urinary undiversion in adults with myelodysplasia: long-term followup. J Urol 1994; 152: 329-333.

5. TREATMENT OF VESICO-URETERAL REFLUX

5.1 Treatment options

The treatment options for vesico-ureteral reflux in patients with NLUTD do not differ essentially from those in other reflux patients. They become necessary when the abolishment of the high intravesical pressure during the filling phase or during the voiding phase have been treated successfully, but where the reflux did not resolve (1-4). Subtrigonal injections with bulking agents or ureteral re-implantation are the standard procedures.

Subtrigonal injections of bulking agents: This minimal invasive procedure has a relatively good effect with complete success in about 65% of patients (5-12). It can also be easily repeated if not effective and thereby the success rate can be increased to about 75% after the second or third session.

Ureteral re-implantation: This technique has an immediate and long-lasting result in over 90% of the patients (11-13).

In deciding which procedure will be offered to the patient, the relative risks of more invasive surgery and of less successful therapy should be considered.

5.2 REFERENCES

1. Kass EJ, Koff SA, Diokno AC. Fate of vesicoureteral reflux in children with neuropathic bladders managed by intermittent catheterization. J Urol 1981; 125: 63-64.
2. Sidi AA, Peng W, Gonzalez R. Vesicoureteral reflux in children with myelodysplasia: natural history and results of treatment. J Urol 1986; 136: 329-331.
3. Lopez Pereira P, Martinez Urrutia MJ, Lobato Romera R, Jaureguizar E. Should we treat vesicoureteral reflux in patients who simultaneously undergo bladder augmentation for neuropathic bladder? J Urol 2001; 165: 2259-2261.
4. Simforoosh N, Tabibi A, Basiri A, Noorbala MH, Danesh AD, Ijadi A. Is ureteral reimplantation necessary during augmentation cystoplasty in patients with neurogenic bladder and vesicoureteral reflux? J Urol 2002; 168: 1439-1441.
5. Diamond T, Boston VE. The natural history of vesicoureteric reflux in children with neuropathic bladder and open neural tube defects. Z Kinderchir 1987; 42 (Suppl 1): 15-16.
6. Chancellor MB, Rivas DA, Liberman SN, Moore J Jr, Staas WE Jr. Cystoscopic autogenous fat injection treatment of vesicoureteral reflux in spinal cord injury. J Am Paraplegia Soc 1994; 17: 50-54.
7. Sugiyama T, Hashimoto K, Kiwamoto H, Ohnishi N, Esa A, Park YC, Kurita T, Kohri K. Endoscopic correction of vesicoureteral reflux in patients with neurogenic bladder dysfunction. Int Urol Nephrol 1995; 27: 527-531.
8. Misra D, Potts SR, Brown S, Boston VE. Endoscopic treatment of vesico-ureteric reflux in neurogenic bladder-8 years' experience. J Pediatr Surg 1996; 31: 1262-1264.
9. Haferkamp A, Mohring K, Staehler G, Gerner HJ, Dorsam J. Long-term efficacy of subureteral collagen injection for endoscopic treatment of vesicoureteral reflux in neurogenic bladder cases. J Urol 2000; 163: 274-277.
10. Shah N, Kabir MJ, Lane T, Avenell S, Shah PJ. Vesico-ureteric reflux in adults with neuropathic bladders treated with Polydimethylsiloxane (Macroplastique). Spinal Cord 2001; 39: 92-96.
11. Engel JD, Palmer LS, Cheng EY, Kaplan WE. Surgical versus endoscopic correction of vesicoureteral reflux in children with neurogenic bladder dysfunction. J Urol 1997; 157: 2291-2294.
12. Granata C, Buffa P, Di Rovasenda E, Mattioli G, Scarsi PL, Podesta E, Dodero P, Jasonni V. Treatment of vesico-ureteric reflux in children with neuropathic bladder: a comparison of surgical and endoscopic correction. J Pediatr Surg 1999; 34: 1836-1838.
13. Kaplan WE, Firlit CF. Management of reflux in the myelodysplastic child. J Urol 1983; 129: 1195-1197.

6. QUALITY OF LIFE

6.1 Considerations

The quality of life is a very important aspect in the treatment of patients with NLUTD. Apart from the limitations that relate directly to the neurologic pathology, the NLUTD can be treated adequately in the majority of patients and must not interfere with social independence. The life expectancy of the patients does not need to be impaired by the NLUTD. With adequate treatment and consequent neuro-urological care over lifetime, the quality of life can be assured.

It is satisfying that this aspect is not neglected (1-12) in the recent medical literature.

6.2 REFERENCES

1. Stöhrer M, Kramer G, Löchner-Ernst D, Goepel M, Noll F, Rübber H. Diagnosis and treatment of bladder dysfunction in spinal cord injury patients. *Eur Urol Update Series* 1994; 3: 170-175.
2. Stone AR. Neurourologic evaluation and urologic management of spinal dysraphism. *Neurosurg Clin N Am* 1995; 6: 269-277.
3. Joseph AC, Juma S, Niku SD. Endourethral prosthesis for treatment of detrusor sphincter dyssynergia: impact on quality of life for persons with spinal cord injury. *SCI Nurs* 1994; 11: 95-99.
4. Breza J, Hornak M, Bardos A, Zvara P. Transformation of the Bricker to a continent urinary reservoir to eliminate severe complications of uretero-ileostomy performed in eight patients among 200 Bricker. *Ann Urol (Paris)* 1995; 29: 227-231.
5. Moreno JG, Chancellor MB, Karasick S, King S, Abdill CK, Rivas DA. Improved quality of life and sexuality with continent urinary diversion in quadriplegic women with umbilical stoma. *Arch Phys Med Rehabil* 1995; 76: 758-762.
6. Bramble FJ. Clinical outcome and quality of life following enterocystoplasty for idiopathic detrusor instability and neurogenic bladder dysfunction. *Br J Urol* 1996; 77: 764-765.
7. Kuo HC. Clinical outcome and quality of life after enterocystoplasty for contracted bladders. *Urol Int* 1997; 58: 160-165.
8. Stöhrer M, Kramer G, Goepel M, Lochner-Ernst D, Kruse D, Rübber H. Bladder autoaugmentation in adult patients with neurogenic voiding dysfunction. *Spinal Cord* 1997; 35: 456-462.
9. Vaidyanathan S, Soni BM, Brown E, Sett P, Krishnan KR, Bingley J, Markey S. Effect of intermittent urethral catheterization and oxybutynin bladder instillation on urinary continence status and quality of life in a selected group of spinal cord injury patients with neuropathic bladder dysfunction. *Spinal Cord* 1998; 36: 409-414.
10. Cranidis A, Nestoridis G. Bladder augmentation. *Int Urogynecol J Pelvic Floor Dysfunct* 2000; 11: 33-40.
11. Nijman RJ. Neurogenic and non-neurogenic bladder dysfunction. *Curr Opin Urol* 2001; 11: 577-583.
12. Kachourbos MJ, Creasey GH. Health promotion in motion: improving quality of life for persons with neurogenic bladder and bowel using assistive technology. *SCI Nurs* 2000; 17: 125-129.

7. FOLLOW-UP

7.1 Considerations

NLUTD is an unstable condition and can vary considerably even within a relatively short period. Meticulous follow-up and regular checks are necessary (1-20). Depending on the type of the underlying neurological pathology and on the present stability of the NLUTD, the interval between the detailed investigations should not exceed 1-2 years. In patients with multiple sclerosis and in acute spinal cord injury this interval is of course much smaller. Urine dip sticks should be available for the patient and urinalysis should be performed at least every second month. The upper urinary tract, the bladder shape, and residual urine should be checked every 6 months. Physical examination and blood and urine laboratory should take place every year. Any sign indicating a risk factor warrants specialized investigation.

7.2 GUIDELINES FOR FOLLOW-UP

1. Possible UTI checked by the patient (dip stick).
2. Urinalysis every second month.
3. Upper urinary tract, bladder morphology, and residual urine every six months (ultrasound)
4. Physical examination, blood chemistry, and urine laboratory every year.
5. Detailed specialistic investigation every 1-2 years and on demand when risk factors emerge. The investigation is specified according to the patient's actual risk profile, but should in any case include a video urodynamic investigation and should be performed in a leading neuro-urological center.
6. All of the above more frequent if the neurological pathology or the NLUTD status demand this.

7.3 REFERENCES

1. Stöhrer M. Alterations in the urinary tract after spinal cord injury - diagnosis, prevention and therapy of late sequelae. *World J Urol* 1990; 7: 205-211.
2. Perkash I. Long-term urologic management of the patient with spinal cord injury. *Urol Clin North Am* 1993; 20: 423-434.
3. Selzman AA, Elder JS, Mapstone TB. Urologic consequences of myelodysplasia and other congenital abnormalities of the spinal cord. *Urol Clin North Am* 1993; 20: 485-504.
4. Stöhrer M, Kramer G, Löchner-Ernst D, Goepel M, Noll F, Rübber H. Diagnosis and treatment of bladder dysfunction in spinal cord injury patients. *Eur Urol Update Series* 1994; 3: 170-175.
5. Thon WF, Denil J, Stief CG, Jonas U. Urologische Langzeitbetreuung von Patienten mit Meningomyelozele. II. Therapie. *Aktuel Urol* 25: 63-76.
6. Waites KB, Canupp KC, DeVivo MJ, Lloyd LK, Dubovsky EV. Compliance with annual urologic evaluations and preservation of renal function in persons with spinal cord injury. *J Spinal Cord Med* 1995; 18: 251-254.
7. Cardenas DD, Mayo ME, Turner LR: Lower urinary changes over time in suprasacral spinal cord injury. *Paraplegia* 1995; 33: 326-329.
8. Capitanucci ML, Iacobelli BD, Silveri M, Mosiello G, De Gennaro M. Long-term urological follow-up of occult spinal dysraphism in children. *Eur J Pediatr Surg* 1996; 6 (Suppl 1): 25-26.
9. Chua HC, Tow A, Tan ES. The neurogenic bladder in spinal cord injury-pattern and management. *Ann Acad Med Singapore* 1996; 25: 553-557.
10. Agarwal SK, Bagli DJ. Neurogenic bladder. *Indian J Pediatr* 1997; 64: 313-326
11. Rashid TM, Hollander JB. Multiple sclerosis and the neurogenic bladder. *Phys Med Rehabil Clin N Am* 1998; 9: 615-629.
12. Burgdörfer H, Heidler H, Madersbacher H, Melchior H, Palmtag H, Richter R, Richter-Reichhelm M, Rist M, Rübber H, Sauerwein D, Schalkhäuser K, Stöhrer M. Leitlinien zur urologischen Betreuung Querschnittgelähmter. *Urologe A* 1998; 37: 222-228.
13. McKinley WO, Jackson AB, Cardenas DD, DeVivo MJ. Long-term medical complications after traumatic spinal cord injury: a regional model systems analysis. *Arch Phys Med Rehabil* 1999 ; 80: 1402-1410.
14. Atan A, Konety BR, Nangia A, Chancellor MB. Advantages and risks of ileovesicostomy for the management of neuropathic bladder. *Urology* 1999; 54: 636-640.
15. Cranidis A, Nestoridis G. Bladder augmentation. *Int Urogynecol J Pelvic Floor Dysfunct* 2000; 11: 33-40.
16. Elliott DS, Boone TB. Recent advances in the management of the neurogenic bladder. *Urology* 2000; 56 (6 Suppl 1): 76-81.
17. Chen Y, DeVivo MJ, Roseman JM. Current trend and risk factors for kidney stones in persons with spinal cord injury: a longitudinal study. *Spinal Cord* 2000; 38: 346-353.
18. Lawrenson R, Wyndaele JJ, Vlachonikolis I, Farmer C, Glickman S. Renal failure in patients with neurogenic lower urinary tract dysfunction. *Neuroepidemiology* 2001; 20: 138-143.
19. Ciancio SJ, Mutchnik SE, Rivera VM, Boone TB. Urodynamic pattern changes in multiple sclerosis.

- Urology 2001; 57: 239-245.
20. Burns AS, Rivas DA, Ditunno JF. The management of neurogenic bladder and sexual dysfunction after spinal cord injury. Spine 2001; 26 (24 Suppl): S129-S136.

8. CONCLUSION

NLUTD is a multi-facetted pathology. It needs an extensive and specific diagnosis before we can embark on an individualized therapy that takes into account the medical and physical condition of the patient, and the patient's expectations about his future social and physical situation with respect to the NLUTD.

The urologist or pediatric urologist can select from a wealth of therapeutical options, each with its specific pros and cons. Notwithstanding the success of any therapy embarked upon, a close surveillance is necessary for all of the patient's life.

With these guidelines we offer you expert advice on how to define the patient's NLUTD condition as precisely as possible and how to select, together with the patient, the appropriate therapy. This last choice, as always, is governed by the golden rule: As effective as needed, as less invasive as possible.

9. ABBREVIATIONS

DLPP	Detrusor leak point pressure
DSD	Detrusor sphincter dyssynergia
EMG	Electromyography, electromyogram
FVC	Frequency volume chart
IC	Intermittent catheterization
ISC	Intermittent self-catheterization
ICS	International Continence Society
LPP	Leak point pressure
LMNL	Lower motor neuron lesion
LUT	Lower urinary tract
LUTD	Lower urinary tract dysfunction
LUTS	Lower urinary tract symptoms
MTC	Micturition time chart
NLUTD	Neurogenic lower urinary tract dysfunction
PNE	Percutaneous nerve evaluation test
SDAF	Sacral deafferentation
SARS	Sacral anterior root stimulation
UMNL	Upper motor neuron lesion
UTI	Urinary tract infection
VUR	Vesico-ureteral reflux